https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Repaglinide&limit=1&skip=0
Page 0 of 18
        "generic_name": [
          "REPAGLINIDE"
        "brand_name": [
          "Prandin"
 
      "drug_interactions": [
        "Drug-Drug Interactions In vitro data indicate that PRANDIN is metabolized by cytochrome P450 enzymes 2C8 and 3A4. Consequently, repaglinide metabolism may be altered by drugs which influence these cytochrome P450 enzyme systems via induction and inhibition. Caution should therefore be used in patients who are on PRANDIN and taking inhibitors and/or inducers of CYP2C8 and CYP3A4. The effect may be very significant if both enzymes are inhibited at the same time resulting in a substantial increase in repaglinide plasma concentrations. Drugs that are known to inhibit CYP3A4 include antifungal agents like ketoconazole, itraconazole, and antibacterial agents like erythromycin. Drugs that are known to inhibit CYP2C8 include agents like trimethoprim, gemfibrozil and montelukast. Drugs that induce the CYP3A4 and/or 2C8 enzyme systems include rifampin, barbiturates, and carbamezapine. See CLINICAL PHARMACOLOGY section, Drug-Drug Interactions . Repaglinide appears to be a substrate for active hepatic uptake transporter (organic anion transporting protein OATP1B1). Drugs that inhibit OATP1B1 (e.g. cyclosporine) may likewise have the potential to increase plasma concentrations of repaglinide. See CLINICAL PHARMACOLOGY section, Drug-Drug Interactions . In vivo data from a study that evaluated the co-administration of a cytochrome P450 enzyme 3A4 inhibitor, clarithromycin, with PRANDIN resulted in a clinically significant increase in repaglinide plasma levels. In addition, an increase in repaglinide plasma levels was observed in studies that evaluated the co-administration of PRANDIN with trimethoprim and PRANDIN with deferasirox, both cytochrome P-450 enzyme 2C8 inhibitors. These increases in repaglinide plasma levels may necessitate a PRANDIN dose adjustment. See CLINICAL PHARMACOLOGY section, Drug-Drug Interactions . Gemfibrozil significantly increased PRANDIN exposure. Therefore, patients should not take PRANDIN with gemfibrozil. See CLINICAL PHARMACOLOGY section, Drug-Drug Interactions , and CONTRAINDICATIONS . The hypoglycemic action of oral blood glucose-lowering agents may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, cyclosporine, chloramphenicol, coumarins, probenecid, monoamine oxidase inhibitors, and beta adrenergic blocking agents. When such drugs are administered to a patient receiving oral blood glucose-lowering agents, the patient should be observed closely for hypoglycemia. When such drugs are withdrawn from a patient receiving oral blood glucose-lowering agents, the patient should be observed closely for loss of glycemic control. Certain drugs tend to produce hyperglycemia and may lead to loss of glycemic control. These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When these drugs are administered to a patient receiving oral blood glucose-lowering agents, the patient should be observed for loss of glycemic control. When these drugs are withdrawn from a patient receiving oral blood glucose-lowering agents, the patient should be observed closely for hypoglycemia."
      "adverse_reactions": [
        "ADVERSE REACTIONS Hypoglycemia: See PRECAUTIONS and OVERDOSAGE sections. PRANDIN has been administered to 2931 individuals during clinical trials. Approximately 1500 of these individuals with type 2 diabetes have been treated for at least 3 months, 1000 for at least 6 months, and 800 for at least 1 year. The majority of these individuals (1228) received PRANDIN in one of five 1-year, active-controlled trials. The comparator drugs in these 1-year trials were oral sulfonylurea drugs (SU) including glyburide and glipizide. Over one year, 13% of PRANDIN patients were discontinued due to adverse events, as were 14% of SU patients. The most common adverse events leading to withdrawal were hyperglycemia, hypoglycemia, and related symptoms (see PRECAUTIONS ). Mild or moderate hypoglycemia occurred in 16% of PRANDIN patients, 20% of glyburide patients, and 19% of glipizide patients. The table below lists common adverse events for PRANDIN patients compared to both placebo (in trials 12 to 24 weeks duration) and to glyburide and glipizide in one year trials. The adverse event profile of PRANDIN was generally comparable to that for sulfonylurea drugs (SU). Commonly Reported Adverse Events (% of Patients)Events >= 2% for the PRANDIN group in the placebo-controlled studies and >= events in the placebo group EVENT PRANDIN PLACEBO PRANDIN SU N = 352 N = 108 N = 1228 N = 498 Placebo controlled studies Active controlled studies Metabolic Hypoglycemia 31See trial description in CLINICAL PHARMACOLOGY, Clinical Trials 7 16 20 Respiratory URI 16 8 10 10 Sinusitis 6 2 3 4 Rhinitis 3 3 7 8 Bronchitis 2 1 6 7 Gastrointestinal Nausea 5 5 3 2 Diarrhea 5 2 4 6 Constipation 3 2 2 3 Vomiting 3 3 2 1 Dyspepsia 2 2 4 2 Musculoskeletal Arthralgia 6 3 3 4 Back Pain 5 4 6 7 Other Headache 11 10 9 8 Paresthesia 3 3 2 1 Chest pain 3 1 2 1 Urinary tract infection 2 1 3 3 Tooth disorder 2 0 <1 <1 Allergy 2 0 1 <1 Cardiovascular Events In one-year trials comparing PRANDIN to sulfonylurea drugs, the incidence of angina was comparable (1.8%) for both treatments, with an incidence of chest pain of 1.8% for PRANDIN and 1.0% for sulfonylureas. The incidence of other selected cardiovascular events (hypertension, abnormal EKG, myocardial infarction, arrhythmias, and palpitations) was <= 1% and not different between PRANDIN and the comparator drugs. The incidence of total serious cardiovascular adverse events, including ischemia, was higher for repaglinide (4%) than for sulfonylurea drugs (3%) in controlled comparator clinical trials. In 1-year controlled trials, PRANDIN treatment was not associated with excess mortality when compared to the rates observed with other oral hypoglycemic agent therapies. Summary of Serious Cardiovascular Events (% of total patients with events) in Trials Comparing PRANDIN to Sulfonylureas PRANDIN SU glyburide and glipizide Total Exposed 1228 498 Serious CV Events 4% 3% Cardiac Ischemic Events 2% 2% Deaths due to CV Events 0.5% 0.4% Seven controlled clinical trials included PRANDIN combination therapy with NPH-insulin (n=431), insulin formulations alone (n=388) or other combinations (sulfonylurea plus NPH-insulin or PRANDIN plus metformin) (n=120). There were six serious adverse events of myocardial ischemia in patients treated with PRANDIN plus NPH-insulin from two studies, and one event in patients using insulin formulations alone from another study. Infrequent Adverse Events (<1% of Patients) Less common adverse clinical or laboratory events observed in clinical trials included elevated liver enzymes, thrombocytopenia, leukopenia, and anaphylactoid reactions. Although no causal relationship with repaglinide has been established, postmarketing experience includes reports of the following rare adverse events: alopecia, hemolytic anemia, pancreatitis, Stevens-Johnson Syndrome, and severe hepatic dysfunction including jaundice and hepatitis. Combination Therapy with Thiazolidinediones During 24-week treatment clinical trials of PRANDIN-rosiglitazone or PRANDIN-pioglitazone combination therapy (a total of 250 patients in combination therapy), hypoglycemia (blood glucose < 50 mg/dL) occurred in 7% of combination therapy patients in comparison to 7% for PRANDIN monotherapy, and 2% for thiazolidinedione monotherapy. Peripheral edema was reported in 12 out of 250 PRANDIN-thiazolidinedione combination therapy patients and 3 out of 124 thiazolidinedione monotherapy patients, with no cases reported in these trials for PRANDIN monotherapy. When corrected for dropout rates of the treatment groups, the percentage of patients having events of peripheral edema per 24 weeks of treatment were 5% for PRANDIN-thiazolidinedione combination therapy, and 4% for thiazolidinedione monotherapy. There were reports in 2 of 250 patients (0.8%) treated with PRANDIN-thiazolidinedione therapy of episodes of edema with congestive heart failure. Both patients had a prior history of coronary artery disease and recovered after treatment with diuretic agents. No comparable cases in the monotherapy treatment groups were reported. Mean change in weight from baseline was +4.9 kg for PRANDIN-thiazolidinedione therapy. There were no patients on PRANDIN-thiazolidinedione combination therapy who had elevations of liver transaminases (defined as 3 times the upper limit of normal levels)."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Repaglinide&limit=1&skip=1
Page 1 of 18
        "generic_name": [
          "REPAGLINIDE"
        "brand_name": [
          "Prandin"
 
      "drug_interactions": [
        "DRUG INTERACTIONS In vitro data indicate that PRANDIN is metabolized by cytochrome P450 enzymes 2C8 and 3A4. Consequently, repaglinide metabolism may be altered by drugs which influence these cytochrome P450 enzyme systems via induction and inhibition. Caution should therefore be used in patients who are on PRANDIN and taking inhibitors and/or inducers of CYP2C8 and CYP3A4. The effect may be very significant if both enzymes are inhibited at the same time resulting in a substantial increase in repaglinide plasma concentrations. Drugs that are known to inhibit CYP3A4 include antifungal agents like ketoconazole, itraconazole, and antibacterial agents like erythromycin. Drugs that are known to inhibit CYP2C8 include agents like trimethoprim, gemfibrozil and montelukast. Drugs that induce the CYP3A4 and/or 2C8 enzyme systems include rifampin, barbiturates, and carbamezapine. See CLINICAL PHARMACOLOGY section,Drug-Drug Interactions. Repaglinide appears to be a substrate for active hepatic uptake transporter (organic anion transporting protein OATP1B1). Drugs that inhibit OATP1B1 (e.g. cyclosporine) may likewise have the potential to increase plasma concentrations of repaglinide. See CLINICAL PHARMACOLOGY section,Drug-Drug Interactions. In vivo data from a study that evaluated the co-administration of a cytochrome P450 enzyme 3A4 inhibitor, clarithromycin, with PRANDIN resulted in a clinically significant increase in repaglinide plasma levels. In addition, an increase in repaglinide plasma levels was observed in studies that evaluated the co-administration of PRANDIN with trimethoprim and PRANDIN with deferasirox, both cytochrome P-450 enzyme 2C8 inhibitors. These increases in repaglinide plasma levels may necessitate a PRANDIN dose adjustment. See CLINICAL PHARMACOLOGY section,Drug-Drug Interactions. Gemfibrozil significantly increased PRANDIN exposure. Therefore, patients should not take PRANDIN with gemfibrozil. See CLINICAL PHARMACOLOGY section,Drug-Drug Interactions, andCONTRAINDICATIONS. The hypoglycemic action of oral blood glucose-lowering agents may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, cyclosporine, chloramphenicol, coumarins, probenecid, monoamine oxidase inhibitors, and beta adrenergic blocking agents. When such drugs are administered to a patient receiving oral blood glucose-lowering agents, the patient should be observed closely for hypoglycemia. When such drugs are withdrawn from a patient receiving oral blood glucose-lowering agents, the patient should be observed closely for loss of glycemic control. Certain drugs tend to produce hyperglycemia and may lead to loss of glycemic control. These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When these drugs are administered to a patient receiving oral blood glucose-lowering agents, the patient should be observed for loss of glycemic control. When these drugs are withdrawn from a patient receiving oral blood glucose-lowering agents, the patient should be observed closely for hypoglycemia."
      "adverse_reactions": [
        "ADVERSE REACTIONS Hypoglycemia: SeePRECAUTIONSandOVERDOSAGEsections. PRANDIN has been administered to 2931 individuals during clinical trials. Approximately 1500 of these individuals with type 2 diabetes have been treated for at least 3 months, 1000 for at least 6 months, and 800 for at least 1 year. The majority of these individuals (1228) received PRANDIN in one of five 1-year, active-controlled trials. The comparator drugs in these 1-year trials were oral sulfonylurea drugs (SU) including glyburide and glipizide. Over one year, 13% of PRANDIN patients were discontinued due to adverse events, as were 14% of SU patients. The most common adverse events leading to withdrawal were hyperglycemia, hypoglycemia, and related symptoms (seePRECAUTIONS). Mild or moderate hypoglycemia occurred in 16% of PRANDIN patients, 20% of glyburide patients, and 19% of glipizide patients. The table below lists common adverse events for PRANDIN patients compared to both placebo (in trials 12 to 24 weeks duration) and to glyburide and glipizide in one year trials. The adverse event profile of PRANDIN was generally comparable to that for sulfonylurea drugs (SU). Commonly Reported Adverse Events (% of Patients)* *Events2% for the PRANDIN group in the placebo-controlled studies andevents in the placebo groupSee trial description in CLINICAL PHARMACOLOGY,Clinical TrialsEVENTPRANDINPLACEBOPRANDINSUN = 352N = 108N = 1228N = 498Placebo controlled studiesActive controlled studiesMetabolicHypoglycemia3171620RespiratoryURI1681010Sinusitis6234Rhinitis3378Bronchitis2167GastrointestinalNausea5532Diarrhea5246Constipation3223Vomiting3321Dyspepsia2242MusculoskeletalArthralgia6334Back Pain5467OtherHeadache111098Paresthesia3321Chest pain3121Urinary tract infection2133Tooth disorder20<1<1Allergy201<1 Cardiovascular Events In one-year trials comparing PRANDIN to sulfonylurea drugs, the incidence of angina was comparable (1.8%) for both treatments, with an incidence of chest pain of 1.8% for PRANDIN and 1.0% for sulfonylureas. The incidence of other selected cardiovascular events (hypertension, abnormal EKG, myocardial infarction, arrhythmias, and palpitations) was1% and not different between PRANDIN and the comparator drugs. The incidence of total serious cardiovascular adverse events, including ischemia, was higher for repaglinide (4%) than for sulfonylurea drugs (3%) in controlled comparator clinical trials. In 1-year controlled trials, PRANDIN treatment was not associated with excess mortality when compared to the rates observed with other oral hypoglycemic agent therapies. Summary of Serious Cardiovascular Events (% of total patients with events) in Trials Comparing PRANDIN to Sulfonylureas *glyburide and glipizidePRANDINSU*Total Exposed1228498Serious CV Events4%3%Cardiac Ischemic Events2%2%Deaths due to CV Events0.5%0.4%Seven controlled clinical trials included PRANDIN combination therapy with NPH-insulin (n=431), insulin formulations alone (n=388) or other combinations (sulfonylurea plus NPH-insulin or PRANDIN plus metformin) (n=120). There were six serious adverse events of myocardial ischemia in patients treated with PRANDIN plus NPH-insulin from two studies, and one event in patients using insulin formulations alone from another study. Infrequent Adverse Events (<1% of Patients) Less common adverse clinical or laboratory events observed in clinical trials included elevated liver enzymes, thrombocytopenia, leukopenia, and anaphylactoid reactions. Although no causal relationship with repaglinide has been established, postmarketing experience includes reports of the following rare adverse events: alopecia, hemolytic anemia, pancreatitis, Stevens-Johnson Syndrome, and severe hepatic dysfunction including jaundice and hepatitis. Combination Therapy with Thiazolidinediones During 24-week treatment clinical trials of PRANDIN-rosiglitazone or PRANDIN-pioglitazone combination therapy (a total of 250 patients in combination therapy), hypoglycemia (blood glucose < 50 mg/dL) occurred in 7% of combination therapy patients in comparison to 7% for PRANDIN monotherapy, and 2% for thiazolidinedione monotherapy. Peripheral edema was reported in 12 out of 250 PRANDIN-thiazolidinedione combination therapy patients and 3 out of 124 thiazolidinedione monotherapy patients, with no cases reported in these trials for PRANDIN monotherapy. When corrected for dropout rates of the treatment groups, the percentage of patients having events of peripheral edema per 24 weeks of treatment were 5% for PRANDIN-thiazolidinedione combination therapy, and 4% for thiazolidinedione monotherapy. There were reports in 2 of 250 patients (0.8%) treated with PRANDIN-thiazolidinedione therapy of episodes of edema with congestive heart failure. Both patients had a prior history of coronary artery disease and recovered after treatment with diuretic agents. No comparable cases in the monotherapy treatment groups were reported. Mean change in weight from baseline was +4.9 kg for PRANDIN-thiazolidinedione therapy. There were no patients on PRANDIN-thiazolidinedione combination therapy who had elevations of liver transaminases (defined as 3 times the upper limit of normal levels)."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Repaglinide&limit=1&skip=2
Page 2 of 18
        "generic_name": [
          "REPAGLINIDE"
        "brand_name": [
          "Prandin"
 
      "drug_interactions": [
        "Drug-Drug Interactions In vitro data indicate that PRANDIN is metabolized by cytochrome P450 enzymes 2C8 and 3A4. Consequently, repaglinide metabolism may be altered by drugs which influence these cytochrome P450 enzyme systems via induction and inhibition. Caution should therefore be used in patients who are on PRANDIN and taking inhibitors and/or inducers of CYP2C8 and CYP3A4. The effect may be very significant if both enzymes are inhibited at the same time resulting in a substantial increase in repaglinide plasma concentrations. Drugs that are known to inhibit CYP3A4 include antifungal agents like ketoconazole, itraconazole, and antibacterial agents like erythromycin. Drugs that are known to inhibit CYP2C8 include agents like trimethoprim, gemfibrozil and montelukast. Drugs that induce the CYP3A4 and/or 2C8 enzyme systems include rifampin, barbiturates, and carbamezapine. See CLINICAL PHARMACOLOGY section, Drug-Drug Interactions . Repaglinide appears to be a substrate for active hepatic uptake transporter (organic anion transporting protein OATP1B1). Drugs that inhibit OATP1B1 (e.g. cyclosporine) may likewise have the potential to increase plasma concentrations of repaglinide. See CLINICAL PHARMACOLOGY section, Drug-Drug Interactions . In vivo data from a study that evaluated the co-administration of a cytochrome P450 enzyme 3A4 inhibitor, clarithromycin, with PRANDIN resulted in a clinically significant increase in repaglinide plasma levels. In addition, an increase in repaglinide plasma levels was observed in studies that evaluated the co-administration of PRANDIN with trimethoprim and PRANDIN with deferasirox, both cytochrome P-450 enzyme 2C8 inhibitors. These increases in repaglinide plasma levels may necessitate a PRANDIN dose adjustment. See CLINICAL PHARMACOLOGY section, Drug-Drug Interactions . Gemfibrozil significantly increased PRANDIN exposure. Therefore, patients should not take PRANDIN with gemfibrozil. See CLINICAL PHARMACOLOGY section, Drug-Drug Interactions , and CONTRAINDICATIONS . The hypoglycemic action of oral blood glucose-lowering agents may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, cyclosporine, chloramphenicol, coumarins, probenecid, monoamine oxidase inhibitors, and beta adrenergic blocking agents. When such drugs are administered to a patient receiving oral blood glucose-lowering agents, the patient should be observed closely for hypoglycemia. When such drugs are withdrawn from a patient receiving oral blood glucose-lowering agents, the patient should be observed closely for loss of glycemic control. Certain drugs tend to produce hyperglycemia and may lead to loss of glycemic control. These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When these drugs are administered to a patient receiving oral blood glucose-lowering agents, the patient should be observed for loss of glycemic control. When these drugs are withdrawn from a patient receiving oral blood glucose-lowering agents, the patient should be observed closely for hypoglycemia."
      "adverse_reactions": [
        "ADVERSE REACTIONS Hypoglycemia: See PRECAUTIONS and OVERDOSAGE sections. PRANDIN has been administered to 2931 individuals during clinical trials. Approximately 1500 of these individuals with type 2 diabetes have been treated for at least 3 months, 1000 for at least 6 months, and 800 for at least 1 year. The majority of these individuals (1228) received PRANDIN in one of five 1-year, active-controlled trials. The comparator drugs in these 1-year trials were oral sulfonylurea drugs (SU) including glyburide and glipizide. Over one year, 13% of PRANDIN patients were discontinued due to adverse events, as were 14% of SU patients. The most common adverse events leading to withdrawal were hyperglycemia, hypoglycemia, and related symptoms (see PRECAUTIONS ). Mild or moderate hypoglycemia occurred in 16% of PRANDIN patients, 20% of glyburide patients, and 19% of glipizide patients. The table below lists common adverse events for PRANDIN patients compared to both placebo (in trials 12 to 24 weeks duration) and to glyburide and glipizide in one year trials. The adverse event profile of PRANDIN was generally comparable to that for sulfonylurea drugs (SU). Commonly Reported Adverse Events (% of Patients)Events >= 2% for the PRANDIN group in the placebo-controlled studies and >= events in the placebo group EVENT PRANDIN PLACEBO PRANDIN SU N = 352 N = 108 N = 1228 N = 498 Placebo controlled studies Active controlled studies Metabolic Hypoglycemia 31See trial description in CLINICAL PHARMACOLOGY, Clinical Trials 7 16 20 Respiratory URI 16 8 10 10 Sinusitis 6 2 3 4 Rhinitis 3 3 7 8 Bronchitis 2 1 6 7 Gastrointestinal Nausea 5 5 3 2 Diarrhea 5 2 4 6 Constipation 3 2 2 3 Vomiting 3 3 2 1 Dyspepsia 2 2 4 2 Musculoskeletal Arthralgia 6 3 3 4 Back Pain 5 4 6 7 Other Headache 11 10 9 8 Paresthesia 3 3 2 1 Chest pain 3 1 2 1 Urinary tract infection 2 1 3 3 Tooth disorder 2 0 <1 <1 Allergy 2 0 1 <1 Cardiovascular Events In one-year trials comparing PRANDIN to sulfonylurea drugs, the incidence of angina was comparable (1.8%) for both treatments, with an incidence of chest pain of 1.8% for PRANDIN and 1.0% for sulfonylureas. The incidence of other selected cardiovascular events (hypertension, abnormal EKG, myocardial infarction, arrhythmias, and palpitations) was <= 1% and not different between PRANDIN and the comparator drugs. The incidence of total serious cardiovascular adverse events, including ischemia, was higher for repaglinide (4%) than for sulfonylurea drugs (3%) in controlled comparator clinical trials. In 1-year controlled trials, PRANDIN treatment was not associated with excess mortality when compared to the rates observed with other oral hypoglycemic agent therapies. Summary of Serious Cardiovascular Events (% of total patients with events) in Trials Comparing PRANDIN to Sulfonylureas PRANDIN SUglyburide and glipizide Total Exposed 1228 498 Serious CV Events 4% 3% Cardiac Ischemic Events 2% 2% Deaths due to CV Events 0.5% 0.4% Seven controlled clinical trials included PRANDIN combination therapy with NPH-insulin (n=431), insulin formulations alone (n=388) or other combinations (sulfonylurea plus NPH-insulin or PRANDIN plus metformin) (n=120). There were six serious adverse events of myocardial ischemia in patients treated with PRANDIN plus NPH-insulin from two studies, and one event in patients using insulin formulations alone from another study. Infrequent Adverse Events (<1% of Patients) Less common adverse clinical or laboratory events observed in clinical trials included elevated liver enzymes, thrombocytopenia, leukopenia, and anaphylactoid reactions. Although no causal relationship with repaglinide has been established, postmarketing experience includes reports of the following rare adverse events: alopecia, hemolytic anemia, pancreatitis, Stevens-Johnson Syndrome, and severe hepatic dysfunction including jaundice and hepatitis. Combination Therapy with Thiazolidinediones During 24-week treatment clinical trials of PRANDIN-rosiglitazone or PRANDIN-pioglitazone combination therapy (a total of 250 patients in combination therapy), hypoglycemia (blood glucose < 50 mg/dL) occurred in 7% of combination therapy patients in comparison to 7% for PRANDIN monotherapy, and 2% for thiazolidinedione monotherapy. Peripheral edema was reported in 12 out of 250 PRANDIN-thiazolidinedione combination therapy patients and 3 out of 124 thiazolidinedione monotherapy patients, with no cases reported in these trials for PRANDIN monotherapy. When corrected for dropout rates of the treatment groups, the percentage of patients having events of peripheral edema per 24 weeks of treatment were 5% for PRANDIN-thiazolidinedione combination therapy, and 4% for thiazolidinedione monotherapy. There were reports in 2 of 250 patients (0.8%) treated with PRANDIN-thiazolidinedione therapy of episodes of edema with congestive heart failure. Both patients had a prior history of coronary artery disease and recovered after treatment with diuretic agents. No comparable cases in the monotherapy treatment groups were reported. Mean change in weight from baseline was +4.9 kg for PRANDIN-thiazolidinedione therapy. There were no patients on PRANDIN-thiazolidinedione combination therapy who had elevations of liver transaminases (defined as 3 times the upper limit of normal levels)."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Repaglinide&limit=1&skip=3
Page 3 of 18
        "generic_name": [
          "REPAGLINIDE"
        "brand_name": [
          "Repaglinide"
 
      "drug_interactions": [
        "Drug-Drug Interactions In vitro data indicate that repaglinide is metabolized by cytochrome P450 enzymes 2C8 and 3A4. Consequently, repaglinide metabolism may be altered by drugs which influence these cytochrome P450 enzyme systems via induction and inhibition. Caution should therefore be used in patients who are on repaglinide and taking inhibitors and/or inducers of CYP2C8 and CYP3A4. The effect may be very significant if both enzymes are inhibited at the same time resulting in a substantial increase in repaglinide plasma concentrations. Drugs that are known to inhibit CYP3A4 include antifungal agents like ketoconazole, itraconazole, and antibacterial agents like erythromycin. Drugs that are known to inhibit CYP2C8 include agents like trimethoprim, gemfibrozil and montelukast. Drugs that induce the CYP3A4 and/or 2C8 enzyme systems include rifampin, barbiturates, and carbamezapine. (See CLINICAL PHARMACOLOGY: Drug-Drug Interactions.) Repaglinide appears to be a substrate for active hepatic uptake transporter (organic anion transporting protein OATP1B1). Drugs that inhibit OATP1B1 (e.g., cyclosporine) may likewise have the potential to increase plasma concentrations of repaglinide. (See CLINICAL PHARMACOLOGY: Drug-Drug Interactions.) In vivo data from a study that evaluated the coadministration of a cytochrome P450 enzyme 3A4 inhibitor, clarithromycin, with repaglinide resulted in a clinically significant increase in repaglinide plasma levels. In addition, an increase in repaglinide plasma levels was observed in studies that evaluated the coadministration of repaglinide with trimethoprim and repaglinide with deferasirox, both cytochrome P450 enzyme 2C8 inhibitors. These increases in repaglinide plasma levels may necessitate a repaglinide dose adjustment. (See CLINICAL PHARMACOLOGY: Drug-Drug Interactions.) Gemfibrozil significantly increased repaglinide exposure. Therefore, patients should not take repaglinide with gemfibrozil. (See CLINICAL PHARMACOLOGY: Drug-Drug Interactions and CONTRAINDICATIONS.) The hypoglycemic action of oral blood glucose-lowering agents may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, cyclosporine, chloramphenicol, coumarins, probenecid, monoamine oxidase inhibitors, and beta-adrenergic blocking agents. When such drugs are administered to a patient receiving oral blood glucose-lowering agents, the patient should be observed closely for hypoglycemia. When such drugs are withdrawn from a patient receiving oral blood glucose-lowering agents, the patient should be observed closely for loss of glycemic control. Certain drugs tend to produce hyperglycemia and may lead to loss of glycemic control. These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When these drugs are administered to a patient receiving oral blood glucose-lowering agents, the patient should be observed for loss of glycemic control. When these drugs are withdrawn from a patient receiving oral blood glucose-lowering agents, the patient should be observed closely for hypoglycemia."
      "adverse_reactions": [
        "ADVERSE REACTIONS Hypoglycemia See PRECAUTIONS and OVERDOSAGE sections. Repaglinide has been administered to 2,931 individuals during clinical trials. Approximately 1,500 of these individuals with type 2 diabetes have been treated for at least 3 months, 1,000 for at least 6 months, and 800 for at least one year. The majority of these individuals (1,228) received repaglinide in 1 of 5 one-year, active-controlled trials. The comparator drugs in these one-year trials were oral sulfonylurea drugs (SU) including glyburide and glipizide. Over one year, 13% of repaglinide patients were discontinued due to adverse events, as were 14% of SU patients. The most common adverse events leading to withdrawal were hyperglycemia, hypoglycemia, and related symptoms (see PRECAUTIONS). Mild or moderate hypoglycemia occurred in 16% of repaglinide patients, 20% of glyburide patients, and 19% of glipizide patients. The table below lists common adverse events for repaglinide patients compared to both placebo (in trials 12 to 24 weeks duration) and to glyburide and glipizide in one year trials. The adverse event profile of repaglinide was generally comparable to that for sulfonylurea drugs (SU). Commonly Reported Adverse Events (% of Patients)Events >= 2% for the repaglinide group in the placebo-controlled studies and >= events in the placebo group EVENT REPAGLINIDE N = 352 PLACEBO N = 108 REPAGLINIDE N = 1,228 SU N = 498 Placebo controlled studies Active controlled studies Metabolic Hypoglycemia 31See trial description in CLINICAL PHARMACOLOGY: Clinical Trials 7 16 20 Respiratory URI Sinusitis Rhinitis Bronchitis 16 6 3 2 8 2 3 1 10 3 7 6 10 4 8 7 Gastrointestinal Nausea Diarrhea Constipation Vomiting Dyspepsia 5 5 3 3 2 5 2 2 3 2 3 4 2 2 4 2 6 3 1 2 Musculoskeletal Arthralgia Back pain 6 5 3 4 3 6 4 7 Other Headache Paresthesia Chest pain Urinary tract infection Tooth disorder Allergy 11 3 3 2 2 2 10 3 1 1 0 0 9 2 2 3 < 1 1 8 1 1 3 < 1 < 1 Cardiovascular Events In one-year trials comparing repaglinide to sulfonylurea drugs, the incidence of angina was comparable (1.8%) for both treatments, with an incidence of chest pain of 1.8% for repaglinide and 1% for sulfonylureas. The incidence of other selected cardiovascular events (hypertension, abnormal EKG, myocardial infarction, arrhythmias, and palpitations) was <= 1% and not different between repaglinide and the comparator drugs. The incidence of total serious cardiovascular adverse events, including ischemia, was higher for repaglinide (4%) than for sulfonylurea drugs (3%) in controlled comparator clinical trials. In one-year controlled trials, repaglinide treatment was not associated with excess mortality when compared to the rates observed with other oral hypoglycemic agent therapies. Summary of Serious Cardiovascular Events (% of Total Patients with Events) in Trials Comparing Repaglinide to Sulfonylureas Repaglinide SUglyburide and glipizide Total Exposed 1,228 498 Serious CV Events 4% 3% Cardiac Ischemic Events 2% 2% Deaths due to CV Events 0.5% 0.4% Seven controlled clinical trials included repaglinide combination therapy with NPH-insulin (n = 431), insulin formulations alone (n = 388) or other combinations (sulfonylurea plus NPH-insulin or repaglinide plus metformin) (n = 120). There were six serious adverse events of myocardial ischemia in patients treated with repaglinide plus NPH-insulin from two studies, and one event in patients using insulin formulations alone from another study. Infrequent Adverse Events (< 1% of Patients) Less common adverse clinical or laboratory events observed in clinical trials included elevated liver enzymes, thrombocytopenia, leukopenia, and anaphylactoid reactions. Although no causal relationship with repaglinide has been established, post-marketing experience includes reports of the following rare adverse events: alopecia, hemolytic anemia, pancreatitis, Stevens-Johnson Syndrome, and severe hepatic dysfunction including jaundice and hepatitis. Combination Therapy with Thiazolidinediones During 24-week treatment clinical trials of repaglinide-rosiglitazone or repaglinide-pioglitazone combination therapy (a total of 250 patients in combination therapy), hypoglycemia (blood glucose < 50 mg/dL) occurred in 7% of combination therapy patients in comparison to 7% for repaglinide monotherapy, and 2% for thiazolidinedione monotherapy. Peripheral edema was reported in 12 out of 250 repaglinide-thiazolidinedione combination therapy patients and 3 out of 124 thiazolidinedione monotherapy patients, with no cases reported in these trials for repaglinide monotherapy. When corrected for dropout rates of the treatment groups, the percentage of patients having events of peripheral edema per 24 weeks of treatment were 5% for repaglinide-thiazolidinedione combination therapy, and 4% for thiazolidinedione monotherapy. There were reports in 2 of 250 patients (0.8%) treated with repaglinide-thiazolidinedione therapy of episodes of edema with congestive heart failure. Both patients had a prior history of coronary artery disease and recovered after treatment with diuretic agents. No comparable cases in the monotherapy treatment groups were reported. Mean change in weight from baseline was +4.9 kg for repaglinide-thiazolidinedione therapy. There were no patients on repaglinide-thiazolidinedione combination therapy who had elevations of liver transaminases (defined as 3 times the upper limit of normal levels)."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Repaglinide&limit=1&skip=4
Page 4 of 18
        "generic_name": [
          "REPAGLINIDE"
        "brand_name": [
          "Repaglinide"
 
      "drug_interactions": [
        "DRUG INTERACTIONS In vitro data indicate that Repaglinide is metabolized by cytochrome P450 enzymes 2C8 and 3A4. Consequently, repaglinide metabolism may be altered by drugs which influence these cytochrome P450 enzyme systems via induction and inhibition. Caution should therefore be used in patients who are on Repaglinide and taking inhibitors and/or inducers of CYP2C8 and CYP3A4. The effect may be very significant if both enzymes are inhibited at the same time resulting in a substantial increase in repaglinide plasma concentrations. Drugs that are known to inhibit CYP3A4 include antifungal agents like ketoconazole, itraconazole, and antibacterial agents like erythromycin. Drugs that are known to inhibit CYP2C8 include agents like trimethoprim, gemfibrozil and montelukast. Drugs that induce the CYP3A4 and/or 2C8 enzyme systems include rifampin, barbiturates, and carbamezapine. See CLINICAL PHARMACOLOGY section, Drug-Drug Interactions. Repaglinide appears to be a substrate for active hepatic uptake transporter (organic anion transporting protein OATP1B1). Drugs that inhibit OATP1B1 (e.g., cyclosporine) may likewise have the potential to increase plasma concentrations of repaglinide. See CLINICAL PHARMACOLOGY section, Drug-Drug Interactions. In vivo data from a study that evaluated the co-administration of a cytochrome P450 enzyme 3A4 inhibitor, clarithromycin, with Repaglinide resulted in a clinically significant increase in repaglinide plasma levels. In addition, an increase in repaglinide plasma levels was observed in a study that evaluated the co-administration of Repaglinide with trimethoprim and Repaglinide with deferasirox, both cytochrome P-450 enzyme 2C8 inhibitors. These increases in repaglinide plasma levels may necessitate a Repaglinide dose adjustment. See CLINICAL PHARMACOLOGY section, Drug-Drug Interactions. Gemfibrozil significantly increased Repaglinide exposure. Therefore, patients should not take Repaglinide with gemfibrozil. See CLINICAL PHARMACOLOGY section, Drug-Drug Interactions, and CONTRAINDICATIONS. The hypoglycemic action of oral blood glucose-lowering agents may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, cyclosporine, chloramphenicol, coumarins, probenecid, monoamine oxidase inhibitors, and beta adrenergic blocking agents. When such drugs are administered to a patient receiving oral blood glucose-lowering agents, the patient should be observed closely for hypoglycemia. When such drugs are withdrawn from a patient receiving oral blood glucose-lowering agents, the patient should be observed closely for loss of glycemic control. Certain drugs tend to produce hyperglycemia and may lead to loss of glycemic control. These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When these drugs are administered to a patient receiving oral blood glucose-lowering agents, the patient should be observed for loss of glycemic control. When these drugs are withdrawn from a patient receiving oral blood glucose-lowering agents, the patient should be observed closely for hypoglycemia."
      "adverse_reactions": [
        "ADVERSE REACTIONS Hypoglycemia: See PRECAUTIONS and OVERDOSAGE sections. Repaglinide has been administered to 2931 individuals during clinical trials. Approximately 1500 of these individuals with type 2 diabetes have been treated for at least 3 months, 1000 for at least 6 months, and 800 for at least 1 year. The majority of these individuals (1228) received Repaglinide in one of five 1-year, active-controlled trials. The comparator drugs in these 1-year trials were oral sulfonylurea drugs (SU) including glyburide and glipizide. Over one year, 13% of Repaglinide patients were discontinued due to adverse events, as were 14% of SU patients. The most common adverse events leading to withdrawal were hyperglycemia, hypoglycemia, and related symptoms (see PRECAUTIONS). Mild or moderate hypoglycemia occurred in 16% of Repaglinide patients, 20% of glyburide patients, and 19% of glipizide patients. The table below lists common adverse events for Repaglinide patients compared to both placebo (in trials 12 to 24 weeks duration) and to glyburide and glipizide in one year trials. The adverse event profile of Repaglinide was generally comparable to that for sulfonylurea drugs (SU). *: Events >=2% for the Repaglinide group in the placebo controlled studies and >= events in the placebo group **: See trial description in CLINICAL PHARMACOLOGY, Clinical Trials Cardiovascular Events In one-year trials comparing Repaglinide to sulfonylurea drugs, the incidence of angina was comparable (1.8%) for both treatments, with an incidence of chest pain of 1.8% for Repaglinide and 1.0% for sulfonylureas. The incidence of other selected cardiovascular events (hypertension, abnormal EKG, myocardial infarction, arrhythmias, and palpitations) was <= 1% and not different between Repaglinide and the comparator drugs. The incidence of total serious cardiovascular adverse events, including ischemia, was higher for repaglinide (4%) than for sulfonylurea drugs (3%) in controlled comparator clinical trials. In 1-year controlled trials, Repaglinide treatment was not associated with excess mortality when compared to the rates observed with other oral hypoglycemic agent therapies. Summary of Serious Cardiovascular Events (% of total patients with events) in Trials Comparing Repaglinide to Sulfonylureas REPAGLINIDE SU* Total Exposed Serious CV Events Cardiac Ischemic Events Deaths due to CV Events 1228 4% 2% 0.5% 498 3% 2% 0.4% *: glyburide and glipizide Seven controlled clinical trials included Repaglinide combination therapy with NPH-insulin (n=431), insulin formulations alone (n=388) or other combinations (sulfonylurea plus NPH insulin) (n=120). There were six serious adverse events of myocardial ischemia in patients treated with Repaglinide plus NPH-insulin from two studies, and one event in patients using insulin formulations alone from another study. Infrequent Adverse Events (<1% of Patients) Less common adverse clinical or laboratory events observed in clinical trials included elevated liver enzymes, thrombocytopenia, leukopenia, and anaphylactoid reactions. Although no causal relationship with repaglinide has been established, postmarketing experience includes reports of the following rare adverse events: alopecia, hemolytic anemia, pancreatitis, Stevens - Johnson Syndrome, and severe hepatic dysfunction including jaundice and hepatitis. Combination Therapy with Thiazolidinediones During 24-week treatment clinical trials of Repaglinide-rosiglitazone or Repaglinide-pioglitazone combination therapy (a total of 250 patients in combination therapy), hypoglycemia (blood glucose < 50 mg/dL) occurred in 7% of combination therapy patients in comparison to 7% for Repaglinide monotherapy, and 2% for thiazolidinedione monotherapy. Peripheral edema was reported in 12 out of 250 Repaglinide-thiazolidinedione combination therapy patients and 3 out of 124 thiazolidinedione monotherapy patients, with no cases reported in these trials for Repaglinide monotherapy. When corrected for dropout rates of the treatment groups, the percentage of patients having events of peripheral edema per 24 weeks of treatment were 5% for Repaglinide-thiazolidinedione combination therapy, and 4% for thiazolidinedione monotherapy. There were reports in 2 of 250 patients (0.8%) treated with Repaglinide-thiazolidinedione therapy of episodes of edema with congestive heart failure. Both patients had a prior history of coronary artery disease and recovered after treatment with diuretic agents. No comparable cases in the monotherapy treatment groups were reported. Mean change in weight from baseline was +4.9 kg for Repaglinide-thiazolidinedione therapy. There were no patients on Repaglinide-thiazolidinedione combination therapy who had elevations of liver transaminases (defined as 3 times the upper limit of normal levels). repaglinide-3"
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Repaglinide&limit=1&skip=5
Page 5 of 18
        "generic_name": [
          "REPAGLINIDE"
        "brand_name": [
          "Prandin"
 
      "drug_interactions": [
        "Drug-Drug Interactions In vitro data indicate that PRANDIN is metabolized by cytochrome P450 enzymes 2C8 and 3A4. Consequently, repaglinide metabolism may be altered by drugs which influence these cytochrome P450 enzyme systems via induction and inhibition. Caution should therefore be used in patients who are on PRANDIN and taking inhibitors and/or inducers of CYP2C8 and CYP3A4. The effect may be very significant if both enzymes are inhibited at the same time resulting in a substantial increase in repaglinide plasma concentrations. Drugs that are known to inhibit CYP3A4 include antifungal agents like ketoconazole, itraconazole, and antibacterial agents like erythromycin. Drugs that are known to inhibit CYP2C8 include agents like trimethoprim, gemfibrozil and montelukast. Drugs that induce the CYP3A4 and/or 2C8 enzyme systems include rifampin, barbiturates, and carbamezapine. See CLINICAL PHARMACOLOGY section, Drug-Drug Interactions . Repaglinide appears to be a substrate for active hepatic uptake transporter (organic anion transporting protein OATP1B1). Drugs that inhibit OATP1B1 (e.g. cyclosporine) may likewise have the potential to increase plasma concentrations of repaglinide. See CLINICAL PHARMACOLOGY section, Drug-Drug Interactions . In vivo data from a study that evaluated the co-administration of a cytochrome P450 enzyme 3A4 inhibitor, clarithromycin, with PRANDIN resulted in a clinically significant increase in repaglinide plasma levels. In addition, an increase in repaglinide plasma levels was observed in studies that evaluated the co-administration of PRANDIN with trimethoprim and PRANDIN with deferasirox, both cytochrome P-450 enzyme 2C8 inhibitors. These increases in repaglinide plasma levels may necessitate a PRANDIN dose adjustment. See CLINICAL PHARMACOLOGY section, Drug-Drug Interactions . Gemfibrozil significantly increased PRANDIN exposure. Therefore, patients should not take PRANDIN with gemfibrozil. See CLINICAL PHARMACOLOGY section, Drug-Drug Interactions , and CONTRAINDICATIONS . The hypoglycemic action of oral blood glucose-lowering agents may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, cyclosporine, chloramphenicol, coumarins, probenecid, monoamine oxidase inhibitors, and beta adrenergic blocking agents. When such drugs are administered to a patient receiving oral blood glucose-lowering agents, the patient should be observed closely for hypoglycemia. When such drugs are withdrawn from a patient receiving oral blood glucose-lowering agents, the patient should be observed closely for loss of glycemic control. Certain drugs tend to produce hyperglycemia and may lead to loss of glycemic control. These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When these drugs are administered to a patient receiving oral blood glucose-lowering agents, the patient should be observed for loss of glycemic control. When these drugs are withdrawn from a patient receiving oral blood glucose-lowering agents, the patient should be observed closely for hypoglycemia."
      "adverse_reactions": [
        "ADVERSE REACTIONS Hypoglycemia: See PRECAUTIONS and OVERDOSAGE sections. PRANDIN has been administered to 2931 individuals during clinical trials. Approximately 1500 of these individuals with type 2 diabetes have been treated for at least 3 months, 1000 for at least 6 months, and 800 for at least 1 year. The majority of these individuals (1228) received PRANDIN in one of five 1-year, active-controlled trials. The comparator drugs in these 1-year trials were oral sulfonylurea drugs (SU) including glyburide and glipizide. Over one year, 13% of PRANDIN patients were discontinued due to adverse events, as were 14% of SU patients. The most common adverse events leading to withdrawal were hyperglycemia, hypoglycemia, and related symptoms (see PRECAUTIONS ). Mild or moderate hypoglycemia occurred in 16% of PRANDIN patients, 20% of glyburide patients, and 19% of glipizide patients. The table below lists common adverse events for PRANDIN patients compared to both placebo (in trials 12 to 24 weeks duration) and to glyburide and glipizide in one year trials. The adverse event profile of PRANDIN was generally comparable to that for sulfonylurea drugs (SU). Commonly Reported Adverse Events (% of Patients)Events >= 2% for the PRANDIN group in the placebo-controlled studies and >= events in the placebo group EVENT PRANDIN PLACEBO PRANDIN SU N = 352 N = 108 N = 1228 N = 498 Placebo controlled studies Active controlled studies Metabolic Hypoglycemia 31See trial description in CLINICAL PHARMACOLOGY, Clinical Trials 7 16 20 Respiratory URI 16 8 10 10 Sinusitis 6 2 3 4 Rhinitis 3 3 7 8 Bronchitis 2 1 6 7 Gastrointestinal Nausea 5 5 3 2 Diarrhea 5 2 4 6 Constipation 3 2 2 3 Vomiting 3 3 2 1 Dyspepsia 2 2 4 2 Musculoskeletal Arthralgia 6 3 3 4 Back Pain 5 4 6 7 Other Headache 11 10 9 8 Paresthesia 3 3 2 1 Chest pain 3 1 2 1 Urinary tract infection 2 1 3 3 Tooth disorder 2 0 <1 <1 Allergy 2 0 1 <1 Cardiovascular Events In one-year trials comparing PRANDIN to sulfonylurea drugs, the incidence of angina was comparable (1.8%) for both treatments, with an incidence of chest pain of 1.8% for PRANDIN and 1.0% for sulfonylureas. The incidence of other selected cardiovascular events (hypertension, abnormal EKG, myocardial infarction, arrhythmias, and palpitations) was <= 1% and not different between PRANDIN and the comparator drugs. The incidence of total serious cardiovascular adverse events, including ischemia, was higher for repaglinide (4%) than for sulfonylurea drugs (3%) in controlled comparator clinical trials. In 1-year controlled trials, PRANDIN treatment was not associated with excess mortality when compared to the rates observed with other oral hypoglycemic agent therapies. Summary of Serious Cardiovascular Events (% of total patients with events) in Trials Comparing PRANDIN to Sulfonylureas PRANDIN SU glyburide and glipizide Total Exposed 1228 498 Serious CV Events 4% 3% Cardiac Ischemic Events 2% 2% Deaths due to CV Events 0.5% 0.4% Seven controlled clinical trials included PRANDIN combination therapy with NPH-insulin (n=431), insulin formulations alone (n=388) or other combinations (sulfonylurea plus NPH-insulin or PRANDIN plus metformin) (n=120). There were six serious adverse events of myocardial ischemia in patients treated with PRANDIN plus NPH-insulin from two studies, and one event in patients using insulin formulations alone from another study. Infrequent Adverse Events (<1% of Patients) Less common adverse clinical or laboratory events observed in clinical trials included elevated liver enzymes, thrombocytopenia, leukopenia, and anaphylactoid reactions. Although no causal relationship with repaglinide has been established, postmarketing experience includes reports of the following rare adverse events: alopecia, hemolytic anemia, pancreatitis, Stevens-Johnson Syndrome, and severe hepatic dysfunction including jaundice and hepatitis. Combination Therapy with Thiazolidinediones During 24-week treatment clinical trials of PRANDIN-rosiglitazone or PRANDIN-pioglitazone combination therapy (a total of 250 patients in combination therapy), hypoglycemia (blood glucose < 50 mg/dL) occurred in 7% of combination therapy patients in comparison to 7% for PRANDIN monotherapy, and 2% for thiazolidinedione monotherapy. Peripheral edema was reported in 12 out of 250 PRANDIN-thiazolidinedione combination therapy patients and 3 out of 124 thiazolidinedione monotherapy patients, with no cases reported in these trials for PRANDIN monotherapy. When corrected for dropout rates of the treatment groups, the percentage of patients having events of peripheral edema per 24 weeks of treatment were 5% for PRANDIN-thiazolidinedione combination therapy, and 4% for thiazolidinedione monotherapy. There were reports in 2 of 250 patients (0.8%) treated with PRANDIN-thiazolidinedione therapy of episodes of edema with congestive heart failure. Both patients had a prior history of coronary artery disease and recovered after treatment with diuretic agents. No comparable cases in the monotherapy treatment groups were reported. Mean change in weight from baseline was +4.9 kg for PRANDIN-thiazolidinedione therapy. There were no patients on PRANDIN-thiazolidinedione combination therapy who had elevations of liver transaminases (defined as 3 times the upper limit of normal levels)."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Repaglinide&limit=1&skip=6
Page 6 of 18
        "generic_name": [
          "REPAGLINIDE"
        "brand_name": [
          "Repaglinide"
 
      "drug_interactions": [
        "Drug-Drug Interactions In vitro data indicate that Repaglinide is metabolized by cytochrome P450 enzymes 2C8 and 3A4. Consequently, repaglinide metabolism may be altered by drugs which influence these cytochrome P450 enzyme systems via induction and inhibition. Caution should therefore be used in patients who are on Repaglinide and taking inhibitors and/or inducers of CYP2C8 and CYP3A4. The effect may be very significant if both enzymes are inhibited at the same time resulting in a substantial increase in repaglinide plasma concentrations. Drugs that are known to inhibit CYP3A4 include antifungal agents like ketoconazole, itraconazole, and antibacterial agents like erythromycin. Drugs that are known to inhibit CYP2C8 include agents like trimethoprim, gemfibrozil and montelukast. Drugs that induce the CYP3A4 and/or 2C8 enzyme systems include rifampin, barbiturates, and carbamezapine. See CLINICAL PHARMACOLOGY section, Drug-Drug Interactions. Repaglinide appears to be a substrate for active hepatic uptake transporter (organic anion transporting protein OATP1B1). Drugs that inhibit OATP1B1 (e.g., cyclosporine) may likewise have the potential to increase plasma concentrations of repaglinide. See CLINICAL PHARMACOLOGY section, Drug-Drug Interactions. In vivo data from a study that evaluated the co-administration of a cytochrome P450 enzyme 3A4 inhibitor, clarithromycin, with Repaglinide resulted in a clinically significant increase in repaglinide plasma levels. In addition, an increase in repaglinide plasma levels was observed in a study that evaluated the co-administration of Repaglinide with trimethoprim and Repaglinide with deferasirox, both cytochrome P-450 enzyme 2C8 inhibitors. These increases in repaglinide plasma levels may necessitate a Repaglinide dose adjustment. See CLINICAL PHARMACOLOGY section, Drug-Drug Interactions. Gemfibrozil significantly increased Repaglinide exposure. Therefore, patients should not take Repaglinide with gemfibrozil. See CLINICAL PHARMACOLOGY section, Drug-Drug Interactions, and CONTRAINDICATIONS. The hypoglycemic action of oral blood glucose-lowering agents may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, cyclosporine, chloramphenicol, coumarins, probenecid, monoamine oxidase inhibitors, and beta adrenergic blocking agents. When such drugs are administered to a patient receiving oral blood glucose-lowering agents, the patient should be observed closely for hypoglycemia. When such drugs are withdrawn from a patient receiving oral blood glucose-lowering agents, the patient should be observed closely for loss of glycemic control. Certain drugs tend to produce hyperglycemia and may lead to loss of glycemic control. These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When these drugs are administered to a patient receiving oral blood glucose-lowering agents, the patient should be observed for loss of glycemic control. When these drugs are withdrawn from a patient receiving oral blood glucose-lowering agents, the patient should be observed closely for hypoglycemia."
      "adverse_reactions": [
        "ADVERSE REACTIONS Hypoglycemia: See PRECAUTIONS and OVERDOSAGE sections. Repaglinide has been administered to 2931 individuals during clinical trials. Approximately 1500 of these individuals with type 2 diabetes have been treated for at least 3 months, 1000 for at least 6 months, and 800 for at least 1 year. The majority of these individuals (1228) received Repaglinide in one of five 1-year, active-controlled trials. The comparator drugs in these 1-year trials were oral sulfonylurea drugs (SU) including glyburide and glipizide. Over one year, 13% of Repaglinide patients were discontinued due to adverse events, as were 14% of SU patients. The most common adverse events leading to withdrawal were hyperglycemia, hypoglycemia, and related symptoms (see PRECAUTIONS ). Mild or moderate hypoglycemia occurred in 16% of Repaglinide patients, 20% of glyburide patients, and 19% of glipizide patients. The table below lists common adverse events for Repaglinide patients compared to both placebo (in trials 12 to 24 weeks duration) and to glyburide and glipizide in one year trials. The adverse event profile of Repaglinide was generally comparable to that for sulfonylurea drugs (SU). *: Events >= 2% for the Repaglinide group in the placebo controlled studies and >= events in the placebo group **: See trial description in CLINICAL PHARMACOLOGY, Clinical Trials Cardiovascular Events In one-year trials comparing Repaglinide to sulfonylurea drugs, the incidence of angina was comparable (1.8%) for both treatments, with an incidence of chest pain of 1.8% for Repaglinide and 1.0% for sulfonylureas. The incidence of other selected cardiovascular events (hypertension, abnormal EKG, myocardial infarction, arrhythmias, and palpitations) was <= 1% and not different between Repaglinide and the comparator drugs. The incidence of total serious cardiovascular adverse events, including ischemia, was higher for repaglinide (4%) than for sulfonylurea drugs (3%) in controlled comparator clinical trials. In 1-year controlled trials, Repaglinide treatment was not associated with excess mortality when compared to the rates observed with other oral hypoglycemic agent therapies. Summary of Serious Cardiovascular Events (% of total patients with events) in Trials Comparing Repaglinide to Sulfonylureas REPAGLINIDE SU glyburide and glipizide Total Exposed Serious CV Events Cardiac Ischemic Events Deaths due to CV Events 1228 4% 2% 0.5% 498 3% 2% 0.4% Seven controlled clinical trials included Repaglinide combination therapy with NPH-insulin (n=431), insulin formulations alone (n=388) or other combinations (sulfonylurea plus NPH insulin) (n=120). There were six serious adverse events of myocardial ischemia in patients treated with Repaglinide plus NPH-insulin from two studies, and one event in patients using insulin formulations alone from another study. Infrequent Adverse Events (<1% of Patients) Less common adverse clinical or laboratory events observed in clinical trials included elevated liver enzymes, thrombocytopenia, leukopenia, and anaphylactoid reactions. Although no causal relationship with repaglinide has been established, postmarketing experience includes reports of the following rare adverse events: alopecia, hemolytic anemia, pancreatitis, Stevens-Johnson Syndrome, and severe hepatic dysfunction including jaundice and hepatitis. Combination Therapy with Thiazolidinediones During 24-week treatment clinical trials of Repaglinide-rosiglitazone or Repaglinide-pioglitazone combination therapy (a total of 250 patients in combination therapy), hypoglycemia (blood glucose < 50 mg/dL) occurred in 7% of combination therapy patients in comparison to 7% for Repaglinide monotherapy, and 2% for thiazolidinedione monotherapy. Peripheral edema was reported in 12 out of 250 Repaglinide-thiazolidinedione combination therapy patients and 3 out of 124 thiazolidinedione monotherapy patients, with no cases reported in these trials for Repaglinide monotherapy. When corrected for dropout rates of the treatment groups, the percentage of patients having events of peripheral edema per 24 weeks of treatment were 5% for Repaglinide-thiazolidinedione combination therapy, and 4% for thiazolidinedione monotherapy. There were reports in 2 of 250 patients (0.8%) treated with Repaglinide-thiazolidinedione therapy of episodes of edema with congestive heart failure. Both patients had a prior history of coronary artery disease and recovered after treatment with diuretic agents. No comparable cases in the monotherapy treatment groups were reported. Mean change in weight from baseline was +4.9 kg for Repaglinide-thiazolidinedione therapy. There were no patients on Repaglinide-thiazolidinedione combination therapy who had elevations of liver transaminases (defined as 3 times the upper limit of normal levels). Commonly Reported Adverse Events"
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Repaglinide&limit=1&skip=7
Page 7 of 18
        "generic_name": [
          "REPAGLINIDE AND METFORMIN HYDROCHLORIDE"
        "brand_name": [
          "PrandiMet"
 
      "drug_interactions": [
        "7 DRUG INTERACTIONS Cationic drugs eliminated by renal tubular secretion may interfere with metformin elimination: use with caution. (7.1) Repaglinide is partly metabolized by CYP2C8 and CYP3A4. Use caution in patients taking inhibitors and/or inducers of CYP2C8 and CYP3A4. (7.2) 7.1 Cationic Drugs Cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, and vancomycin) that are eliminated by renal tubular secretion theoretically have the potential for interaction with metformin by competing for common renal tubular transport systems. Careful patient monitoring and dose adjustment of PrandiMet and/or the interfering drug is recommended in patients who are taking cationic medications that are excreted via the proximal renal tubular secretory system [see Clinical Pharmacology (12.3) ]. 7.2 CYP2C8 and CYP3A4 Inhibitors/Inducers Repaglinide is metabolized by CYP2C8 and to a lesser extent by CYP3A4. Drugs that inhibit 2C8 (gemfibrozil, trimethoprim, deferasirox), inhibit 3A4 (itraconazole, ketaconazole), or induce CYP2C8/3A4 (rifampin) may alter the pharmacokinetics and pharmacodynamics of repaglinide. In vivo data from a study that evaluated the co-administration of gemfibrozil and repaglinide in healthy subjects showed a significant increase in repaglinide blood levels. Administration of PrandiMet and gemfibrozil to the same patient is not recommended [see Warnings and Precautions (5.7) and Clinical Pharmacology (12.3) ]. Repaglinide exposures are increased more than 20-fold in patients taking both gemfibrozil and itraconazole [see Contraindications (4) and Clinical Pharmacology (12.3) ]."
      "adverse_reactions": [
        "6 ADVERSE REACTIONS Hypoglycemia and headache were the most common adverse reactions (>=10%) reported among patients treated with repaglinide in combination with metformin HCl, occurring more frequently than among patients treated with repaglinide alone or metformin HCl alone. (6.2) Gastrointestinal reactions (e.g., diarrhea, nausea and vomiting) are the most common adverse reactions with metformin HCl treatment and are more frequent at higher metformin HCl doses. (6.1, 6.2) To report SUSPECTED ADVERSE REACTIONS, contact Novo Nordisk at 1-800-727-6500 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Most Frequently Observed Adverse Reactions Repaglinide In clinical trials of repaglinide, hypoglycemia is the most common adverse reaction (> 5%) leading to withdrawal of patients treated with repaglinide. Metformin HCl Gastrointestinal reactions (e.g., diarrhea, nausea, vomiting) are the most common adverse reactions (> 5%) with metformin HCl treatment and are more frequent at higher metformin HCl doses. 6.2 Clinical Trial Experience Because clinical trials are conducted under varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Patients with Inadequate Glycemic Control on Metformin HCl Monotherapy Table 1 summarizes the most common adverse reactions occurring in a 6-month randomized study of repaglinide added to metformin HCl in patients with type 2 diabetes inadequately controlled on metformin HCl alone. Table 1: Repaglinide added to metformin HCl in patients with type 2 diabetes inadequately controlled on metformin HCl alone. Adverse reaction reported (regardless of Investigator Assessment of Causality) in >=10% of patients receiving combination therapyIntent to treat population Coadministered repaglinide and metformin HCl Metformin HCl monotherapy Repaglinide monotherapy N (%) N (%) N (%) No. of Patients Exposed 27 27 28 Gastrointestinal System Disorder 9 (33) 13 (48) 10 (36) Diarrhea 5 (19) 8 (30) 2 (7) Nausea 4 (15) 2 (7) 1 (4) Symptomatic HypoglycemiaThere were no cases of severe hypoglycemia (hypoglycemia requiring the assistance of another person) 9 (33) 0 (0) 3 (11) Headache 6 (22) 4 (15) 3 (11) Upper Respiratory Tract Infection 3 (11) 3 (11) 3 (11) Cardiovascular Events in repaglinide monotherapy trials In one-year trials comparing repaglinide to sulfonylurea drugs, the incidence of angina was 1.8% for both treatments, with an incidence of chest pain of 1.8% for repaglinide and 1.0% for sulfonylureas. The incidence of other selected cardiovascular events (hypertension, abnormal electrocardiogram, myocardial infarction, arrhythmias, and palpitations) was <= 1% and not different between repaglinide and the comparator drugs. The incidence of total serious cardiovascular adverse events, including ischemia, was higher for repaglinide (51/1228 or 4%) than for sulfonylurea drugs (13/498 or 3%) in controlled clinical trials. In 1-year controlled trials, repaglinide treatment was not associated with excess mortality when compared to the rates observed with other oral hypoglycemic agent therapies such as glyburide and glipizide. Seven controlled clinical trials included repaglinide combination therapy with NPH-insulin (n=431), insulin formulations alone (n=388) or other combinations (sulfonylurea plus NPH-insulin or repaglinide plus metformin HCl) (n=120). There were six serious adverse events of myocardial ischemia in patients treated with repaglinide plus NPH-insulin (1.4%) from two studies, and one event in patients using insulin formulations alone from another study (0.3%) [ see Warnings and Precautions (5.6) ]. 6.3 Postmarketing Experience Repaglinide The following additional adverse reactions have been identified during postapproval use of repaglinide. Because these reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or a causal relationship to drug exposure. Postmarketing experience with repaglinide includes infrequent reports of the following adverse events; alopecia, hemolytic anemia, pancreatitis, Stevens-Johnson Syndrome, and severe hepatic dysfunction including jaundice and hepatitis."
      "warnings_and_cautions": [
        "5 WARNINGS AND PRECAUTIONS Metformin HCl is contraindicated in renal impairment. Assess renal function before initiating PrandiMet and at least annually thereafter, and verify as normal. (4, 5.2) Temporarily discontinue PrandiMet in patients receiving iodinated contrast for radiological studies. (5.3) Hepatic impairment is associated with lactic acidosis. Recommend not using in patients with hepatic impairment. (5.4) Alcohol potentiates the effect of metformin on lactate metabolism. Warn patients against excess alcohol intake. (5.5) PrandiMet should not be used in combination with NPH insulin. (5.6) Gemfibrozil substantially increases repaglinide exposure. Coadministration of gemfibrozil and PrandiMet is not recommended. (4, 5.7, 7.2, 12.3) The repaglinide component can cause hypoglycemia. Initiate PrandiMet at the lowest available dose in patients naive to meglitinide therapy. (5.8) Metformin can cause vitamin B12 deficiency. Measure hematological parameters annually. (5.9) May need to discontinue PrandiMet and temporarily use insulin if glycemic control deteriorates during periods of stress or if there is decreased intake of fluids and food (e.g., infection, surgery). (5.10) There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with PrandiMet or any other oral anti-diabetic drug. (5.15) 5.1 Lactic Acidosis Metformin hydrochloride Lactic acidosis is a rare, but serious, metabolic complication that can occur due to metformin accumulation during treatment with PrandiMet; when it occurs, it is fatal in approximately 50% of cases. Lactic acidosis may also occur in association with a number of pathophysiologic conditions, including diabetes mellitus, and whenever there is significant tissue hypoperfusion and hypoxemia. Lactic acidosis is characterized by elevated blood lactate levels (>5 mmol/L), decreased blood pH, electrolyte disturbances with an increased anion gap, and an increased lactate/pyruvate ratio. When metformin is implicated as the cause of lactic acidosis, metformin plasma levels >5 g/mL are generally found. The reported incidence of lactic acidosis in patients receiving metformin HCl is very low (approximately 0.03 cases/1,000 patient-years of exposure, with approximately 0.015 fatal cases/1,000 patient-years of exposure). In more than 20,000 patient-years exposure to metformin HCl in clinical trials, there were no reports of lactic acidosis. Reported cases have occurred primarily in diabetic patients with significant renal impairment, including both intrinsic renal disease and renal hypoperfusion, often in the setting of multiple concomitant medical/surgical problems and multiple concomitant medications. Patients with congestive heart failure requiring pharmacologic management, in particular those with unstable or acute congestive heart failure who are at risk of hypoperfusion and hypoxemia, are at increased risk of lactic acidosis. The risk of lactic acidosis increases with the degree of renal impairment and the patient's age. The risk of lactic acidosis may, therefore, be significantly decreased by regular monitoring of renal function in patients taking PrandiMet and by use of the minimum effective dose of PrandiMet. In particular, treatment of the elderly should be accompanied by careful monitoring of renal function. Treatment with PrandiMet should not be initiated in patients >=80 years of age unless measurement of creatinine clearance demonstrates that renal function is not reduced, as these patients are more susceptible to developing lactic acidosis. In addition, PrandiMet should be promptly withheld in the presence of any condition associated with hypoxemia, dehydration, or sepsis. Because impaired hepatic function may significantly limit the ability to clear lactate, PrandiMet should generally be avoided in patients with clinical or laboratory evidence of hepatic disease. Patients should be cautioned against excessive alcohol intake, either acute or chronic, when taking PrandiMet, since alcohol potentiates the effects of metformin HCl on lactate metabolism. In addition, PrandiMet should be temporarily discontinued prior to any intravascular radiocontrast study and for any surgical procedure [see Warnings and Precautions (5.3), (5.5), and (5.10)]. The onset of lactic acidosis often is subtle, and accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, increasing somnolence, and nonspecific abdominal distress. There may be associated hypothermia, hypotension, and resistant bradyarrhythmias with more marked acidosis. The patient and the patient's physician must be aware of the possible importance of such symptoms and the patient should be instructed to notify the physician immediately if they occur (see also Warnings and Precautions). PrandiMet should be withdrawn until the situation is clarified. Serum electrolytes, ketones, blood glucose and, if indicated, blood pH, lactate levels, and even blood metformin levels may be useful. Once a patient is stabilized on any dose level of PrandiMet, gastrointestinal symptoms, which are common during initiation of therapy, are unlikely to be drug related. Later occurrence of gastrointestinal symptoms could be due to lactic acidosis or other serious disease. Levels of fasting venous plasma lactate above the upper limit of normal but less than 5 mmol/L in patients taking PrandiMet do not necessarily indicate impending lactic acidosis and may be explainable by other mechanisms, such as poorly controlled diabetes or obesity, vigorous physical activity or technical problems in sample handling [see Warnings and Precautions (5.11), (5.14)]. Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia). Lactic acidosis is a medical emergency that must be treated in a hospital setting. In a patient with lactic acidosis who is taking PrandiMet, the drug should be discontinued immediately and general supportive measures promptly instituted. Because metformin HCl is dialyzable (with a clearance of up to 170 mL/min under good hemodynamic conditions), prompt hemodialysis is recommended to correct the acidosis and remove the accumulated metformin. Such management often results in prompt reversal of symptoms and recovery [see Contraindications (4) ]. 5.2 Impaired Renal Function Patients with renal impairment should not receive PrandiMet [see Warnings and Precautions (5.1), Contraindications (4) ]. As metformin is substantially excreted by the kidney, before initiation of therapy with PrandiMet and at least annually thereafter, renal function should be assessed and verified as normal. In patients in whom development of renal impairment is anticipated, renal function should be assessed more frequently and PrandiMet discontinued if evidence of renal impairment is present [see Clinical Pharmacology (12.3) ]. 5.3 Radiologic Studies with Intravascular Iodinated Contrast Materials Intravascular contrast studies with iodinated materials can lead to acute alteration of renal function and have been associated with lactic acidosis in patients receiving metformin HCl [see Contraindications (4) ]. Therefore, in patients in whom any such study is planned, PrandiMet should be temporarily discontinued at the time of or prior to the procedure, and withheld for 48 hours subsequent to the procedure and reinstituted only after renal function has been re-evaluated and found to be normal. 5.4 Impaired Hepatic Function Hepatic impairment has been associated with some cases of lactic acidosis. Therefore, PrandiMet should generally be avoided in patients with hepatic impairment [see Clinical Pharmacology (12.3) ]. 5.5 Alcohol Intake Alcohol potentiates the effect of metformin on lactate metabolism. Patients should be warned against excessive alcohol intake while receiving PrandiMet. 5.6 Combination with NPH-insulin Repaglinide Repaglinide is not indicated for use in combination with NPH-insulin. Across seven controlled clinical trials, there were six serious adverse events (1.4%) of myocardial ischemia with repaglinide in combination with NPH-insulin compared to one event (0.3%) in patients using insulin alone [see Adverse Reactions (6.2) ]. 5.7 Drug Interactions Repaglinide is partly metabolized by CYP2C8 and CYP3A4 and appears to be a substrate for active hepatic uptake transporter (organic anion transporting protein OATP1B1). Drugs that inhibit CYP2C8, CYP3A4, or OATP1B1 (e.g., cyclosporine) may increase plasma concentrations of repaglinide . Dose reduction of repaglinide may be needed [see Drug Interactions (7.2) and Clinical Pharmacology (12.3) ]. Gemfibrozil significantly increased repaglinide exposure. Therefore, patients should not take PrandiMet with gemfibrozil [see Contraindications (4) and Clinical Pharmacology (12.3) ]. 5.8 Hypoglycemia Most blood glucose-lowering drugs, including repaglinide, can cause hypoglycemia. Patients who have not previously been treated with a meglitinide should be started on the lowest available repaglinide component of PrandiMet to reduce the risk of hypoglycemia. Elderly, debilitated or malnourished patients and those with adrenal or pituitary insufficiency or alcohol intoxication are particularly susceptible to hypoglycemia. Hypoglycemia may be difficult to recognize in the elderly and in people who are taking -adrenergic blocking drugs [see Adverse Reactions (6.1) ]. 5.9 Vitamin B12 Levels In controlled clinical trials of metformin HCl of 29 weeks' duration, a decrease to subnormal levels of previously normal serum vitamin B12 levels, without clinical manifestations, was observed in approximately 7% of patients. This finding, possibly due to interference with B12 absorption from the B12-intrinsic factor complex, is rarely associated with anemia and appears to be rapidly reversible with discontinuation of metformin HCl or vitamin B12 supplementation. Measurement of hematologic parameters on an annual basis is advised in patients on PrandiMet and any apparent abnormalities should be appropriately investigated and managed. Certain individuals (those with inadequate vitamin B12 or calcium intake or absorption) appear to be predisposed to developing subnormal vitamin B12 levels. In these patients, routine serum vitamin B12 measurements at 2- to 3-year intervals may be useful. 5.10 Surgical Procedures Use of PrandiMet should be temporarily suspended for any surgical procedure (except minor procedures not associated with restricted intake of food and fluids) and should not be restarted until the patient's oral intake has resumed and renal function has been evaluated as normal. 5.11 Loss of Control of Blood Glucose When a patient stabilized on any diabetic regimen is exposed to stress such as fever, trauma, infection, or surgery, a temporary loss of glycemic control may occur. At such times, it may be necessary to withhold PrandiMet and temporarily administer insulin. PrandiMet may be reinstituted after the acute episode is resolved. 5.12 Use of Concomitant Medications Affecting Renal Function or Metformin Disposition Concomitant medication(s) that may affect renal function or result in significant hemodynamic change or may interfere with the disposition of metformin, such as cationic drugs that are eliminated by renal tubular secretion [see Drug Interactions (7.1) ] should be used with caution. 5.13 Hypoxic States Cardiovascular collapse (shock) from whatever cause, acute congestive heart failure, acute myocardial infarction, and other conditions characterized by hypoxemia have been associated with lactic acidosis and may also cause prerenal azotemia. When such events occur in patients receiving PrandiMet, the drug should be promptly discontinued. 5.14 Change in Clinical Status of Patients with Previously Controlled Type 2 Diabetes A patient with type 2 diabetes previously well-controlled on PrandiMet who develops laboratory abnormalities or clinical illness (especially vague and poorly defined illness) should be evaluated promptly for evidence of ketoacidosis or lactic acidosis. Evaluation should include serum electrolytes and ketones, blood glucose and, if indicated, blood pH, lactate, pyruvate, and metformin levels. If acidosis of either form occurs, PrandiMet must be stopped immediately and other appropriate corrective measures initiated. 5.15 Macrovascular Outcomes There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with PrandiMet or any other oral anti-diabetic drug."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Repaglinide&limit=1&skip=8
Page 8 of 18
        "generic_name": [
          "REPAGLINIDE"
        "brand_name": [
          "Repaglinide"
 
      "drug_interactions": [
        "Drug-Drug Interactions In vitro data indicate that repaglinide is metabolized by cytochrome P450 enzymes 2C8 and 3A4. Consequently, repaglinide metabolism may be altered by drugs which influence these cytochrome P450 enzyme systems via induction and inhibition. Caution should therefore be used in patients who are on repaglinide and taking inhibitors and/or inducers of CYP2C8 and CYP3A4. The effect may be very significant if both enzymes are inhibited at the same time resulting in a substantial increase in repaglinide plasma concentrations. Drugs that are known to inhibit CYP3A4 include antifungal agents like ketoconazole, itraconazole, and antibacterial agents like erythromycin. Drugs that are known to inhibit CYP2C8 include agents like trimethoprim, gemfibrozil and montelukast. Drugs that induce the CYP3A4 and/or 2C8 enzyme systems include rifampin, barbiturates, and carbamezapine. See CLINICAL PHARMACOLOGY section, Drug-Drug Interactions . Repaglinide appears to be a substrate for active hepatic uptake transporter (organic anion transporting protein OATP1B1). Drugs that inhibit OATP1B1 (e.g., cyclosporine) may likewise have the potential to increase plasma concentrations of repaglinide. See CLINICAL PHARMACOLOGY section, Drug-Drug Interactions . In vivo data from a study that evaluated the co-administration of a cytochrome P450 enzyme 3A4 inhibitor, clarithromycin, with repaglinide resulted in a clinically significant increase in repaglinide plasma levels. In addition, an increase in repaglinide plasma levels was observed in studies that evaluated the co-administration of repaglinide with trimethoprim and repaglinide with deferasirox, both cytochrome P-450 enzyme 2C8 inhibitors. These increases in repaglinide plasma levels may necessitate a repaglinide dose adjustment. See CLINICAL PHARMACOLOGY section, Drug-Drug Interactions . Gemfibrozil significantly increased repaglinide exposure. Therefore, patients should not take repaglinide with gemfibrozil. See CLINICAL PHARMACOLOGY section, Drug-Drug Interactions , and CONTRAINDICATIONS . The hypoglycemic action of oral blood glucose-lowering agents may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, cyclosporine, chloramphenicol, coumarins, probenecid, monoamine oxidase inhibitors, and beta adrenergic blocking agents. When such drugs are administered to a patient receiving oral blood glucose-lowering agents, the patient should be observed closely for hypoglycemia. When such drugs are withdrawn from a patient receiving oral blood glucose-lowering agents, the patient should be observed closely for loss of glycemic control. Certain drugs tend to produce hyperglycemia and may lead to loss of glycemic control. These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When these drugs are administered to a patient receiving oral blood glucose-lowering agents, the patient should be observed for loss of glycemic control. When these drugs are withdrawn from a patient receiving oral blood glucose-lowering agents, the patient should be observed closely for hypoglycemia."
      "adverse_reactions": [
        "ADVERSE REACTIONS Hypoglycemia: See PRECAUTIONS and OVERDOSAGE sections. Repaglinide has been administered to 2931 individuals during clinical trials. Approximately 1500 of these individuals with type 2 diabetes have been treated for at least 3 months, 1000 for at least 6 months, and 800 for at least 1 year. The majority of these individuals (1228) received repaglinide in one of five 1-year, active-controlled trials. The comparator drugs in these 1-year trials were oral sulfonylurea drugs (SU) including glyburide and glipizide. Over one year, 13% of repaglinide patients were discontinued due to adverse events, as were 14% of SU patients. The most common adverse events leading to withdrawal were hyperglycemia, hypoglycemia, and related symptoms (see PRECAUTIONS ). Mild or moderate hypoglycemia occurred in 16% of repaglinide patients, 20% of glyburide patients, and 19% of glipizide patients. The table below lists common adverse events for repaglinide patients compared to both placebo (in trials 12 to 24 weeks duration) and to glyburide and glipizide in one year trials. The adverse event profile of repaglinide was generally comparable to that for sulfonylurea drugs (SU). Commonly Reported Adverse Events (% of Patients)* EVENT Repaglinide N = 352 PLACEBO N = 108 Repaglinide N = 1228 SU N = 498 Placebo Controlled Studies Active Controlled Studies *: Events >2% for the repaglinide group in the placebo-controlled studies and >= events in the placebo group **: See trial description in CLINICAL PHARMACOLOGY, Clinical Trials Metabolic Hypoglycemia 31** 7 16 20 Respiratory URI 16 8 10 10 Sinusitis 6 2 3 4 Rhinitis 3 3 7 8 Bronchitis 2 1 6 7 Gastrointestinal Nausea 5 5 3 2 Diarrhea 5 2 4 6 Constipation 3 2 2 3 Vomiting 3 3 2 1 Dyspepsia 2 2 4 2 Musculoskeletal Arthralgia 6 3 3 4 Back Pain 5 4 6 7 Other Headache 11 10 9 8 Paresthesia 3 3 2 1 Chest Pain 3 1 2 1 Urinary Tract Infection 2 1 3 3 Tooth Disorder 2 0 <1 <1 Allergy 2 0 1 <1 Cardiovascular Events In one-year trials comparing repaglinide to sulfonylurea drugs, the incidence of angina was comparable (1.8%) for both treatments, with an incidence of chest pain of 1.8% for repaglinide and 1% for sulfonylureas. The incidence of other selected cardiovascular events (hypertension, abnormal EKG, myocardial infarction, arrhythmias, and palpitations) was <= 1% and not different between repaglinide and the comparator drugs. The incidence of total serious cardiovascular adverse events, including ischemia, was higher for repaglinide (4%) than for sulfonylurea drugs (3%) in controlled comparator clinical trials. In 1-year controlled trials, repaglinide treatment was not associated with excess mortality when compared to the rates observed with other oral hypoglycemic agent therapies. Summary of Serious Cardiovascular Events (% of total patients with events) in Trials Comparing Repaglinide to Sulfonylureas Total Exposed Repaglinide SU* 1228 498 *: glyburide and glipizide Serious CV Events 4% 3% Cardiac Ischemic Events 2% 2% Deaths due to CV Events 0.5% 0.4% Seven controlled clinical trials included repaglinide combination therapy with NPH-insulin (n=431), insulin formulations alone (n=388) or other combinations (sulfonylurea plus NPH-insulin or repaglinide plus metformin) (n=120). There were six serious adverse events of myocardial ischemia in patients treated with repaglinide plus NPH-insulin from two studies, and one event in patients using insulin formulations alone from another study. Infrequent Adverse Events (<1% of Patients) Less common adverse clinical or laboratory events observed in clinical trials included elevated liver enzymes, thrombocytopenia, leukopenia, and anaphylactoid reactions. Although no causal relationship with repaglinide has been established, postmarketing experience includes reports of the following rare adverse events: alopecia, hemolytic anemia, pancreatitis, Stevens-Johnson syndrome, and severe hepatic dysfunction including jaundice and hepatitis. Combination Therapy with Thiazolidinediones During 24-week treatment clinical trials of repaglinide-rosiglitazone or repaglinide-pioglitazone combination therapy (a total of 250 patients in combination therapy), hypoglycemia (blood glucose < 50 mg/dL) occurred in 7% of combination therapy patients in comparison to 7% for repaglinide monotherapy, and 2% for thiazolidinedione monotherapy. Peripheral edema was reported in 12 out of 250 repaglinide-thiazolidinedione combination therapy patients and 3 out of 124 thiazolidinedione monotherapy patients, with no cases reported in these trials for repaglinide monotherapy. When corrected for dropout rates of the treatment groups, the percentage of patients having events of peripheral edema per 24 weeks of treatment were 5% for repaglinide-thiazolidinedione combination therapy, and 4% for thiazolidinedione monotherapy. There were reports in 2 of 250 patients (0.8%) treated with repaglinide-thiazolidinedione therapy of episodes of edema with congestive heart failure. Both patients had a prior history of coronary artery disease and recovered after treatment with diuretic agents. No comparable cases in the monotherapy treatment groups were reported. Mean change in weight from baseline was +4.9 kg for repaglinide-thiazolidinedione therapy. There were no patients on repaglinide-thiazolidinedione combination therapy who had elevations of liver transaminases (defined as 3 times the upper limit of normal levels)."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Repaglinide&limit=1&skip=9
Page 9 of 18
        "generic_name": [
          "REPAGLINIDE"
        "brand_name": [
          "Prandin"
 
      "drug_interactions": [
        "Drug-Drug Interactions data indicate that PRANDIN is metabolized by cytochrome P450 enzymes 2C8 and 3A4. Consequently, repaglinide metabolism may be altered by drugs which influence these cytochrome P450 enzyme systems via induction and inhibition. Caution should therefore be used in patients who are on PRANDIN and taking inhibitors and/or inducers of CYP2C8 and CYP3A4. The effect may be very significant if both enzymes are inhibited at the same time resulting in a substantial increase in repaglinide plasma concentrations. Drugs that are known to inhibit CYP3A4 include antifungal agents like ketoconazole, itraconazole, and antibacterial agents like erythromycin. Drugs that are known to inhibit CYP2C8 include agents like trimethoprim, gemfibrozil and montelukast. Drugs that induce the CYP3A4 and/or 2C8 enzyme systems include rifampin, barbiturates, and carbamezapine. See section, . In vitro CLINICAL PHARMACOLOGY Drug-Drug Interactions Repaglinide appears to be a substrate for active hepatic uptake transporter (organic anion transporting protein OATP1B1). Drugs that inhibit OATP1B1 (e.g. cyclosporine) may likewise have the potential to increase plasma concentrations of repaglinide. See section, . CLINICAL PHARMACOLOGY Drug-Drug Interactions data from a study that evaluated the co-administration of a cytochrome P450 enzyme 3A4 inhibitor, clarithromycin, with PRANDIN resulted in a clinically significant increase in repaglinide plasma levels. In addition, an increase in repaglinide plasma levels was observed in studies that evaluated the co-administration of PRANDIN with trimethoprim and PRANDIN with deferasirox, both cytochrome P-450 enzyme 2C8 inhibitors. These increases in repaglinide plasma levels may necessitate a PRANDIN dose adjustment. See section, . In vivo CLINICAL PHARMACOLOGY Drug-Drug Interactions Gemfibrozil significantly increased PRANDIN exposure. Therefore, patients should not take PRANDIN with gemfibrozil. See section, , and . CLINICAL PHARMACOLOGY Drug-Drug Interactions CONTRAINDICATIONS The hypoglycemic action of oral blood glucose-lowering agents may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, cyclosporine, chloramphenicol, coumarins, probenecid, monoamine oxidase inhibitors, and beta adrenergic blocking agents. When such drugs are administered to a patient receiving oral blood glucose-lowering agents, the patient should be observed closely for hypoglycemia. When such drugs are withdrawn from a patient receiving oral blood glucose-lowering agents, the patient should be observed closely for loss of glycemic control. Certain drugs tend to produce hyperglycemia and may lead to loss of glycemic control. These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When these drugs are administered to a patient receiving oral blood glucose-lowering agents, the patient should be observed for loss of glycemic control. When these drugs are withdrawn from a patient receiving oral blood glucose-lowering agents, the patient should be observed closely for hypoglycemia."
      "adverse_reactions": [
        "ADVERSE REACTIONS Hypoglycemia: See and sections. PRECAUTIONS OVERDOSAGE PRANDIN has been administered to 2931 individuals during clinical trials. Approximately 1500 of these individuals with type 2 diabetes have been treated for at least 3 months, 1000 for at least 6 months, and 800 for at least 1 year. The majority of these individuals (1228) received PRANDIN in one of five 1-year, active-controlled trials. The comparator drugs in these 1-year trials were oral sulfonylurea drugs (SU) including glyburide and glipizide. Over one year, 13% of PRANDIN patients were discontinued due to adverse events, as were 14% of SU patients. The most common adverse events leading to withdrawal were hyperglycemia, hypoglycemia, and related symptoms (see ). Mild or moderate hypoglycemia occurred in 16% of PRANDIN patients, 20% of glyburide patients, and 19% of glipizide patients. PRECAUTIONS The table below lists common adverse events for PRANDIN patients compared to both placebo (in trials 12 to 24 weeks duration) and to glyburide and glipizide in one year trials. The adverse event profile of PRANDIN was generally comparable to that for sulfonylurea drugs (SU). Commonly Reported Adverse Events (% of Patients) Events >= 2% for the PRANDIN group in the placebo-controlled studies and >= events in the placebo group EVENT PRANDIN PLACEBO PRANDIN SU N = 352 N = 108 N = 1228 N = 498 Placebo controlled studies Active controlled studies Metabolic Hypoglycemia 31 See trial description in , CLINICAL PHARMACOLOGY Clinical Trials 7 16 20 Respiratory URI 16 8 10 10 Sinusitis 6 2 3 4 Rhinitis 3 3 7 8 Bronchitis 2 1 6 7 Gastrointestinal Nausea 5 5 3 2 Diarrhea 5 2 4 6 Constipation 3 2 2 3 Vomiting 3 3 2 1 Dyspepsia 2 2 4 2 Musculoskeletal Arthralgia 6 3 3 4 Back Pain 5 4 6 7 Other Headache 11 10 9 8 Paresthesia 3 3 2 1 Chest pain 3 1 2 1 Urinary tract infection 2 1 3 3 Tooth disorder 2 0 <1 <1 Allergy 2 0 1 <1 Cardiovascular Events In one-year trials comparing PRANDIN to sulfonylurea drugs, the incidence of angina was comparable (1.8%) for both treatments, with an incidence of chest pain of 1.8% for PRANDIN and 1.0% for sulfonylureas. The incidence of other selected cardiovascular events (hypertension, abnormal EKG, myocardial infarction, arrhythmias, and palpitations) was <= 1% and not different between PRANDIN and the comparator drugs. The incidence of total serious cardiovascular adverse events, including ischemia, was higher for repaglinide (4%) than for sulfonylurea drugs (3%) in controlled comparator clinical trials. In 1-year controlled trials, PRANDIN treatment was not associated with excess mortality when compared to the rates observed with other oral hypoglycemic agent therapies. Summary of Serious Cardiovascular Events (% of total patients with events) in Trials Comparing PRANDIN to Sulfonylureas PRANDIN SU glyburide and glipizide Total Exposed 1228 498 Serious CV Events 4% 3% Cardiac Ischemic Events 2% 2% Deaths due to CV Events 0.5% 0.4% Seven controlled clinical trials included PRANDIN combination therapy with NPH-insulin (n=431), insulin formulations alone (n=388) or other combinations (sulfonylurea plus NPH-insulin or PRANDIN plus metformin) (n=120). There were six serious adverse events of myocardial ischemia in patients treated with PRANDIN plus NPH-insulin from two studies, and one event in patients using insulin formulations alone from another study. Infrequent Adverse Events (<1% of Patients) Less common adverse clinical or laboratory events observed in clinical trials included elevated liver enzymes, thrombocytopenia, leukopenia, and anaphylactoid reactions. Although no causal relationship with repaglinide has been established, postmarketing experience includes reports of the following rare adverse events: alopecia, hemolytic anemia, pancreatitis, Stevens-Johnson Syndrome, and severe hepatic dysfunction including jaundice and hepatitis. Combination Therapy with Thiazolidinediones During 24-week treatment clinical trials of PRANDIN-rosiglitazone or PRANDIN-pioglitazone combination therapy (a total of 250 patients in combination therapy), hypoglycemia (blood glucose < 50 mg/dL) occurred in 7% of combination therapy patients in comparison to 7% for PRANDIN monotherapy, and 2% for thiazolidinedione monotherapy. Peripheral edema was reported in 12 out of 250 PRANDIN-thiazolidinedione combination therapy patients and 3 out of 124 thiazolidinedione monotherapy patients, with no cases reported in these trials for PRANDIN monotherapy. When corrected for dropout rates of the treatment groups, the percentage of patients having events of peripheral edema per 24 weeks of treatment were 5% for PRANDIN-thiazolidinedione combination therapy, and 4% for thiazolidinedione monotherapy. There were reports in 2 of 250 patients (0.8%) treated with PRANDIN-thiazolidinedione therapy of episodes of edema with congestive heart failure. Both patients had a prior history of coronary artery disease and recovered after treatment with diuretic agents. No comparable cases in the monotherapy treatment groups were reported. Mean change in weight from baseline was +4.9 kg for PRANDIN-thiazolidinedione therapy. There were no patients on PRANDIN-thiazolidinedione combination therapy who had elevations of liver transaminases (defined as 3 times the upper limit of normal levels)."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Repaglinide&limit=1&skip=10
Page 10 of 18
        "generic_name": [
          "REPAGLINIDE"
        "brand_name": [
          "Repaglinide"
 
      "drug_interactions": [
        "Drug-Drug Interactions In vitro data indicate that Repaglinide Tablets, USP is metabolized by cytochrome P450 enzymes 2C8 and 3A4. Consequently, repaglinide metabolism may be altered by drugs which influence these cytochrome P450 enzyme systems via induction and inhibition. Caution should therefore be used in patients who are on Repaglinide Tablets, USP and taking inhibitors and/or inducers of CYP2C8 and CYP3A4. The effect may be very significant if both enzymes are inhibited at the same time resulting in a substantial increase in repaglinide plasma concentrations. Drugs that are known to inhibit CYP3A4 include antifungal agents like ketoconazole, itraconazole, and antibacterial agents like erythromycin. Drugs that are known to inhibit CYP2C8 include agents like trimethoprim, gemfibrozil and montelukast. Drugs that induce the CYP3A4 and/or 2C8 enzyme systems include rifampin, barbiturates, and carbamezapine. See CLINICAL PHARMACOLOGY section, Drug-Drug Interactions . Repaglinide appears to be a substrate for active hepatic uptake transporter (organic anion transporting protein OATP1B1). Drugs that inhibit OATP1B1 (e.g. cyclosporine) may likewise have the potential to increase plasma concentrations of repaglinide. See CLINICAL PHARMACOLOGY section, Drug-Drug Interactions. In vivo data from a study that evaluated the co-administration of a cytochrome P450 enzyme 3A4 inhibitor, clarithromycin, with repaglinide resulted in a clinically significant increase in repaglinide plasma levels. In addition, an increase in repaglinide plasma levels was observed in studies that evaluated the co-administration of repaglinide with trimethoprim and repaglinide with deferasirox, both cytochrome P-450 enzyme 2C8 inhibitors. These increases in repaglinide plasma levels may necessitate a Repaglinide Tablets, USP dose adjustment. See CLINICAL PHARMACOLOGY section, Drug-Drug Interactions . Gemfibrozil significantly increased repaglinide exposure. Therefore, patients should not take Repaglinide Tablets, USP with gemfibrozil. See CLINICAL PHARMACOLOGY section, Drug-Drug Interactions , and CONTRAINDICATIONS . The hypoglycemic action of oral blood glucose-lowering agents may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, cyclosporine, chloramphenicol, coumarins, probenecid, monoamine oxidase inhibitors, and beta adrenergic blocking agents. When such drugs are administered to a patient receiving oral blood glucose-lowering agents, the patient should be observed closely for hypoglycemia. When such drugs are withdrawn from a patient receiving oral blood glucose-lowering agents, the patient should be observed closely for loss of glycemic control. Certain drugs tend to produce hyperglycemia and may lead to loss of glycemic control. These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When these drugs are administered to a patient receiving oral blood glucose-lowering agents, the patient should be observed for loss of glycemic control. When these drugs are withdrawn from a patient receiving oral blood glucose-lowering agents, the patient should be observed closely for hypoglycemia."
      "adverse_reactions": [
        "ADVERSE REACTIONS Hypoglycemia: See PRECAUTIONS and OVERDOSAGE sections. Repaglinide Tablets, USP have been administered to 2931 individuals during clinical trials. Approximately 1500 of these individuals with type 2 diabetes have been treated for at least 3 months, 1000 for at least 6 months, and 800 for at least 1 year. The majority of these individuals (1228) received Repaglinide Tablets, USP in one of five 1-year, active-controlled trials. The comparator drugs in these 1-year trials were oral sulfonylurea drugs (SU) including glyburide and glipizide. Over one year, 13% of Repaglinide Tablets, USP patients were discontinued due to adverse events, as were 14% of SU patients. The most common adverse events leading to withdrawal were hyperglycemia, hypoglycemia, and related symptoms (see PRECAUTIONS ). Mild or moderate hypoglycemia occurred in 16% of Repaglinide Tablets, USP patients, 20% of glyburide patients, and 19% of glipizide patients. The table below lists common adverse events for Repaglinide Tablets, USP patients compared to both placebo (in trials 12 to 24 weeks duration) and to glyburide and glipizide in one year trials. The adverse event profile of Repaglinide Tablets, USP was generally comparable to that for sulfonylurea drugs (SU). Commonly Reported Adverse Events (% of Patients): Events >= 2% for the Repaglinide Tablets, USP group in the placebo-controlled studies and >= events in the placebo group EVENT Repaglinide Tablets, USP Placebo Repaglinide Tablets, USP SU N = 352 N = 108 N = 1228 N = 498 Placebo controlled studies Active controlled studies Metabolic Hypoglycemia 31: See trial description in CLINICAL PHARMACOLOGY, Clinical Trials 7 16 20 Respiratory URI 16 8 10 10 Sinusitis 6 2 3 4 Rhinitis 3 3 7 8 Bronchitis 2 1 6 7 Gastrointestinal Nausea 5 5 3 2 Diarrhea 5 2 4 6 Constipation 3 2 2 3 Vomiting 3 3 2 1 Dyspepsia 2 2 4 2 Musculoskeletal Arthralgia 6 3 3 4 Back Pain 5 4 6 7 Other Headache 11 10 9 8 Paresthesia 3 3 2 1 Chest pain 3 1 2 1 Urinary tract infection 2 1 3 3 Tooth disorder 2 0 <1 <1 Allergy 2 0 1 <1 Cardiovascular Events In one-year trials comparing Repaglinide Tablets, USP to sulfonylurea drugs, the incidence of angina was comparable (1.8%) for both treatments, with an incidence of chest pain of 1.8% for Repaglinide Tablets, USP and 1.0% for sulfonylureas. The incidence of other selected cardiovascular events (hypertension, abnormal EKG, myocardial infarction, arrhythmias, and palpitations) was <= 1% and not different between Repaglinide Tablets, USP and the comparator drugs. The incidence of total serious cardiovascular adverse events, including ischemia, was higher for repaglinide (4%) than for sulfonylurea drugs (3%) in controlled comparator clinical trials. In 1 year controlled trials, Repaglinide Tablets, USP treatment was not associated with excess mortality when compared to the rates observed with other oral hypoglycemic agent therapies. Summary of Serious Cardiovascular Events (% of total patients with events) in Trials Comparing Repaglinide Tablets, USP to Sulfonylureas Repaglinide Tablets, USP SU: glyburide and glipizide Total Exposed 1228 498 Serious CV Events 4% 3% Cardiac Ischemic Events 2% 2% Deaths due to CV Events 0.5% 0.4% Other controlled clinical trials included Repaglinide Tablets, USP combination therapy with NPH-insulin (n=431), insulin formulations alone (n=388) or sulfonylurea plus NPH-insulin. There were six serious adverse events of myocardial ischemia in patients treated with Repaglinide Tablets, USP plus NPH-insulin from two studies, and one event in patients using insulin formulations alone from another study. Infrequent Adverse Events (<1% of Patients) Less common adverse clinical or laboratory events observed in clinical trials included elevated liver enzymes, thrombocytopenia, leukopenia, and anaphylactoid reactions. Although no causal relationship with repaglinide has been established, postmarketing experience includes reports of the following rare adverse events: alopecia, hemolytic anemia, pancreatitis, Stevens-Johnson Syndrome, and severe hepatic dysfunction including jaundice and hepatitis. Combination Therapy with Thiazolidinediones During 24-week treatment clinical trials of repaglinide-rosiglitazone or repaglinide-pioglitazone combination therapy (a total of 250 patients in combination therapy), hypoglycemia (blood glucose < 50 mg/dL) occurred in 7% of combination therapy patients in comparison to 7% for repaglinide monotherapy, and 2% for thiazolidinedione monotherapy. Peripheral edema was reported in 12 out of 250 repaglinide-thiazolidinedione combination therapy patients and 3 out of 124 thiazolidinedione monotherapy patients, with no cases reported in these trials for repaglinide monotherapy. When corrected for dropout rates of the treatment groups, the percentage of patients having events of peripheral edema per 24 weeks of treatment were 5% for repaglinide-thiazolidinedione combination therapy, and 4% for thiazolidinedione monotherapy. There were reports in 2 of 250 patients (0.8%) treated with repaglinide thiazolidinedione therapy of episodes of edema with congestive heart failure. Both patients had a prior history of coronary artery disease and recovered after treatment with diuretic agents. No comparable cases in the monotherapy treatment groups were reported. Mean change in weight from baseline was +4.9 kg for repaglinide-thiazolidinedione therapy. There were no patients on repaglinide-thiazolidinedione combination therapy who had elevations of liver transaminases (defined as 3 times the upper limit of normal levels)."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Repaglinide&limit=1&skip=11
Page 11 of 18
        "generic_name": [
          "REPAGLINIDE"
        "brand_name": [
          "Repaglinide"
 
      "adverse_reactions": [
        "ADVERSE REACTIONS Hypoglycemia See PRECAUTIONS and OVERDOSAGE sections. Repaglinide has been administered to 2931 individuals during clinical trials. Approximately 1500 of these individuals with type 2 diabetes have been treated for at least 3 months, 1000 for at least 6 months, and 800 for at least 1 year. The majority of these individuals (1228) received repaglinide in one of five 1-year, active-controlled trials. The comparator drugs in these 1-year trials were oral sulfonylurea drugs (SU) including glyburide and glipizide. Over one year, 13% of repaglinide patients were discontinued due to adverse events, as were 14% of SU patients. The most common adverse events leading to withdrawal were hyperglycemia, hypoglycemia, and related symptoms (see PRECAUTIONS). Mild or moderate hypoglycemia occurred in 16% of repaglinide patients, 20% of glyburide patients, and 19% of glipizide patients. The table below lists common adverse events for repaglinide patients compared to both placebo (in trials 12 to 24 weeks duration) and to glyburide and glipizide in one year trials. The adverse event profile of repaglinide was generally comparable to that for sulfonylurea drugs (SU). Commonly Reported Adverse Events (% of Patients )* * EVENT Repaglinide N = 352 Placebo N=108 Repaglinide N=1228 SU N = 498 Placebo controlled studies Active controlled studies Metabolic Hypoglycemia 31See trial description in CLINICAL PHARMACOLOGY, Clinical Trials 7 16 20 Respiratory URI 16 8 10 10 Sinusitis 6 2 3 4 Rhinitis 3 3 7 8 Bronchitis 2 1 6 7 Gastrointestinal Nausea 5 5 3 2 Diarrhea 5 2 4 6 Constipation 3 2 2 3 Vomiting 3 3 2 1 Dyspepsia 2 2 4 2 Musculoskeletal Arthralgia 6 3 3 4 Back Pain 5 4 6 7 Other Headache 11 10 9 8 Paresthesia 3 3 2 1 Chest pain 3 1 2 1 Urinary tract infection 2 1 3 3 Tooth disorder 2 0 <1 <1 Allergy 2 0 1 <1 ** Events >=2% for the repaglinide group in the placebo-controlled studies and >= events in the placebo group Cardiovascular Events In one-year trials comparing repaglinide to sulfonylurea drugs, the incidence of angina was comparable (1.8%) for both treatments, with an incidence of chest pain of 1.8% for repaglinide and 1% for sulfonylureas. The incidence of other selected cardiovascular events (hypertension, abnormal EKG, myocardial infarction, arrhythmias, and palpitations) was <=1% and not different between repaglinide and the comparator drugs. The incidence of total serious cardiovascular adverse events, including ischemia, was higher for repaglinide (4%) than for sulfonylurea drugs (3%) in controlled comparator clinical trials. In 1-year controlled trials, repaglinide treatment was not associated with excess mortality when compared to the rates observed with other oral hypoglycemic agent therapies. Summary of Serious Cardiovascular Events (% of total patients with events) in Trials Comparing Repaglinide to Sulfonylureas Repaglinide SU glyburide and glipizide Total Exposed 1228 498 Serious CV Events 4% 3% Cardiac Ischemic Events 2% 2% Deaths due to CV Events 0.5% 0.4% Seven controlled clinical trials included repaglinide combination therapy with NPH-insulin (n=431), insulin formulations alone (n=388) or other combinations (sulfonylurea plus NPH-insulin or repaglinide plus metformin) (n=120). There were six serious adverse events of myocardial ischemia in patients treated with repaglinide plus NPH-insulin from two studies, and one event in patients using insulin formulations alone from another study. Infrequent Adverse Events (<1% of Patients) Less common adverse clinical or laboratory events observed in clinical trials included elevated liver enzymes, thrombocytopenia, leukopenia, and anaphylactoid reactions. Although no causal relationship with repaglinide has been established, postmarketing experience includes reports of the following rare adverse events: alopecia, hemolytic anemia, pancreatitis, Stevens-Johnson Syndrome, and severe hepatic dysfunction including jaundice and hepatitis. Combination Therapy with Thiazolidinediones During 24-week treatment clinical trials of repaglinide-rosiglitazone or repaglinide-pioglitazone combination therapy (a total of 250 patients in combination therapy), hypoglycemia (blood glucose <50 mg/dL) occurred in 7% of combination therapy patients in comparison to 7% for repaglinide monotherapy, and 2% for thiazolidinedione monotherapy. Peripheral edema was reported in 12 out of 250 repaglinide-thiazolidinedione combination therapy patients and 3 out of 124 thiazolidinedione monotherapy patients, with no cases reported in these trials for repaglinide monotherapy. When corrected for dropout rates of the treatment groups, the percentage of patients having events of peripheral edema per 24 weeks of treatment were 5% for repaglinide-thiazolidinedione combination therapy, and 4% for thiazolidinedione monotherapy. There were reports in 2 of 250 patients (0.8%) treated with repaglinide-thiazolidinedione therapy of episodes of edema with congestive heart failure. Both patients had a prior history of coronary artery disease and recovered after treatment with diuretic agents. No comparable cases in the monotherapy treatment groups were reported. Mean change in weight from baseline was +4.9 kg for repaglinide-thiazolidinedione therapy. There were no patients on repaglinide-thiazolidinedione combination therapy who had elevations of liver transaminases (defined as 3 times the upper limit of normal levels)."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Repaglinide&limit=1&skip=12
Page 12 of 18
        "generic_name": [
          "REPAGLINIDE"
        "brand_name": [
          "REPAGLINIDE"
 
      "drug_interactions": [
        "Drug-Drug Interactions In vitro data indicate that Repaglinide is metabolized by cytochrome P450 enzymes 2C8 and 3A4. Consequently, repaglinide metabolism may be altered by drugs which influence these cytochrome P450 enzyme systems via induction and inhibition. Caution should therefore be used in patients who are on Repaglinide and taking inhibitors and/or inducers of CYP2C8 and CYP3A4. The effect may be very significant if both enzymes are inhibited at the same time resulting in a substantial increase in repaglinide plasma concentrations. Drugs that are known to inhibit CYP3A4 include antifungal agents like ketoconazole, itraconazole, and antibacterial agents like erythromycin. Drugs that are known to inhibit CYP2C8 include agents like trimethoprim, gemfibrozil and montelukast. Drugs that induce the CYP3A4 and/or 2C8 enzyme systems include rifampin, barbiturates, and carbamezapine. See CLINICAL PHARMACOLOGY section, Drug-Drug Interactions. Repaglinide appears to be a substrate for active hepatic uptake transporter (organic anion transporting protein OATP1B1). Drugs that inhibit OATP1B1 (e.g. cyclosporine) may likewise have the potential to increase plasma concentrations of repaglinide. See CLINICAL PHARMACOLOGY section, Drug-Drug Interactions. In vivo data from a study that evaluated the co-administration of a cytochrome P450 enzyme 3A4 inhibitor, clarithromycin, with Repaglinide resulted in a clinically significant increase in repaglinide plasma levels. In addition, an increase in repaglinide plasma levels was observed in studies that evaluated the co-administration of Repaglinide with trimethoprim and Repaglinide with deferasirox, both cytochrome P-450 enzyme 2C8 inhibitors. These increases in repaglinide plasma levels may necessitate a Repaglinide dose adjustment. See CLINICAL PHARMACOLOGYsection, Drug-Drug Interactions. Gemfibrozil significantly increased Repaglinide exposure. Therefore, patients should not take Repaglinide with gemfibrozil. See CLINICAL PHARMACOLOGY section, Drug-Drug Interactions. , and CONTRAINDICATIONS,. The hypoglycemic action of oral blood glucose-lowering agents may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, cyclosporine, chloramphenicol, coumarins, probenecid, monoamine oxidase inhibitors, and beta adrenergic blocking agents. When such drugs are administered to a patient receiving oral blood glucose-lowering agents, the patient should be observed closely for hypoglycemia. When such drugs are withdrawn from a patient receiving oral blood glucose-lowering agents, the patient should be observed closely for loss of glycemic control. Certain drugs tend to produce hyperglycemia and may lead to loss of glycemic control. These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When these drugs are administered to a patient receiving oral blood glucose-lowering agents, the patient should be observed for loss of glycemic control. When these drugs are withdrawn from a patient receiving oral blood glucose-lowering agents, the patient should be observed closely for hypoglycemia."
      "adverse_reactions": [
        "ADVERSE REACTIONS Hypoglycemia: See PRECAUTIONS and OVERDOSAGE sections. Repaglinide has been administered to 2931 individuals during clinical trials. Approximately 1500 of these individuals with type 2 diabetes have been treated for at least 3 months, 1000 for at least 6 months, and 800 for at least 1 year. The majority of these individuals (1228) received Repaglinide in one of five 1-year, active-controlled trials. The comparator drugs in these 1-year trials were oral sulfonylurea drugs (SU) including glyburide and glipizide. Over one year, 13% of Repaglinide patients were discontinued due to adverse events, as were 14% of SU patients. The most common adverse events leading to withdrawal were hyperglycemia, hypoglycemia, and related symptoms (see PRECAUTIONS). Mild or moderate hypoglycemia occurred in 16% of Repaglinidepatients, 20% of glyburide patients, and 19% of glipizide patients. The table below lists common adverse events for Repaglinide patients compared to both placebo (in trials 12 to 24 weeks duration) and to glyburide and glipizide in one year trials. The adverse event profile of Repaglinide was generally comparable to that for sulfonylurea drugs (SU). Commonly Reported Adverse Events (% of Patients)* *: Events >= 2% for the Repaglinide group in the placebo controlled studies and >= events in the placebo group **: See trial description in CLINICAL PHARMACOLOGY,Clinical Trials EVENT REPAGLINIDE PLACEBO REPAGLINIDE SU N = 352 N = 108 N = 1228 N = 498 Placebo controlled studies Active controlled studies Metabolic Hypoglycemia 31** 7 16 20 Respiratory URI 16 8 10 10 Sinusitis 6 2 3 4 Rhinitis 3 3 7 8 Bronchitis 2 1 6 7 Gastrointestinal Nausea 5 5 3 2 Diarrhea 5 2 4 6 Constipation 3 2 2 3 Vomiting 3 3 2 1 Dyspepsia 2 2 4 2 Musculoskeletal Arthralgia 6 3 3 4 Back Pain 5 4 6 7 Other Headache 11 10 9 8 Paresthesia 3 3 2 1 Chest Pain 3 1 2 1 Urinary tract infection 2 1 3 3 Tooth disorder 2 0 <1 <1 Allergy 2 0 1 <1 Cardiovascular Events In one-year trials comparing Repaglinide to sulfonylurea drugs, the incidence of angina was comparable (1.8%) for both treatments, with an incidence of chest pain of 1.8% for Repaglinide and 1.0% for sulfonylureas. The incidence of other selected cardiovascular events (hypertension, abnormal EKG, myocardial infarction, arrhythmias, and palpitations) was <= 1% and not different between Repaglinide and the comparator drugs. The incidence of total serious cardiovascular adverse events, including ischemia, was higher for repaglinide (4%) than for sulfonylurea drugs (3%) in controlled comparator clinical trials. In 1-year controlled trials, Repaglinide treatment was not associated with excess mortality when compared to the rates observed with other oral hypoglycemic agent therapies. Summary of Serious Cardiovascular Events (% of total patients with events) in Trials Comparing Repaglinide to Sulfonylureas *: glyburide and glipizide REPAGLINIDE SU* Total Exposed 1228 498 Serious CV Events 4% 3% Cardiac Ischemic Events 2% 2% Deaths due to CV Events 0.5% 0.4% Seven controlled clinical trials included Repaglinide combination therapy with NPH-insulin (n=431), insulin formulations alone (n=388) or other combinations (sulfonylurea plus NPH-insulin or Repaglinide plus metformin) (n=120). There were six serious adverse events of myocardial ischemia in patients treated with Repaglinide plus NPH-insulin from two studies, and one event in patients using insulin formulations alone from another study. Infrequent Adverse Events (<1% of Patients) Less common adverse clinical or laboratory events observed in clinical trials included elevated liver enzymes, thrombocytopenia, leukopenia, and anaphylactoid reactions. Although no causal relationship with repaglinide has been established, postmarketing experience includes reports of the following rare adverse events: alopecia, hemolytic anemia, pancreatitis, Stevens-Johnson Syndrome, and severe hepatic dysfunction including jaundice and hepatitis. Combination Therapy with Thiazolidinediones During 24-week treatment clinical trials of Repaglinide-rosiglitazone or Repaglinide-pioglitazone combination therapy (a total of 250 patients in combination therapy), hypoglycemia (blood glucose < 50 mg/dL) occurred in 7% of combination therapy patients in comparison to 7% for Repaglinide monotherapy, and 2% for thiazolidinedione monotherapy. Peripheral edema was reported in 12 out of 250 Repaglinide-thiazolidinedione combination therapy patients and 3 out of 124 thiazolidinedione monotherapy patients, with no cases reported in these trials for Repaglinide monotherapy. When corrected for dropout rates of the treatment groups, the percentage of patients having events of peripheral edema per 24 weeks of treatment were 5% for Repaglinide-thiazolidinedione combination therapy, and 4% for thiazolidinedione monotherapy. There were reports in 2 of 250 patients (0.8%) treated with Repaglinide-thiazolidinedione therapy of episodes of edema with congestive heart failure. Both patients had a prior history of coronary artery disease and recovered after treatment with diuretic agents. No comparable cases in the monotherapy treatment groups were reported. Mean change in weight from baseline was +4.9 kg for Repaglinide-thiazolidinedione therapy. There were no patients on Repaglinide-thiazolidinedione combination therapy who had elevations of liver transaminases (defined as 3 times the upper limit of normal levels)."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Repaglinide&limit=1&skip=13
Page 13 of 18
        "generic_name": [
          "REPAGLINIDE"
        "brand_name": [
          "Prandin"
 
      "adverse_reactions": [
        "ADVERSE REACTIONSHypoglycemia: See PRECAUTIONS and OVERDOSAGE sections. PRANDIN has been administered to 2931 individuals during clinical trials. Approximately 1500 of these individuals with type 2 diabetes have been treated for at least 3 months, 1000 for at least 6 months, and 800 for at least 1 year. The majority of these individuals (1228) received PRANDIN in one of five 1-year, active-controlled trials. The comparator drugs in these 1-year trials were oral sulfonylurea drugs (SU) including glyburide and glipizide. Over one year, 13% of PRANDIN patients were discontinued due to adverse events, as were 14% of SU patients. The most common adverse events leading to withdrawal were hyperglycemia, hypoglycemia, and related symptoms (see PRECAUTIONS ). Mild or moderate hypoglycemia occurred in 16% of PRANDIN patients, 20% of glyburide patients, and 19% of glipizide patients. The table below lists common adverse events for PRANDIN patients compared to both placebo (in trials 12 to 24 weeks duration) and to glyburide and glipizide in one year trials. The adverse event profile of PRANDIN was generally comparable to that for sulfonylurea drugs (SU). Cardiovascular Events In one-year trials comparing PRANDIN to sulfonylurea drugs, the incidence of angina was comparable (1.8%) for both treatments, with an incidence of chest pain of 1.8% for PRANDIN and 1.0% for sulfonylureas. The incidence of other selected cardiovascular events (hypertension, abnormal EKG, myocardial infarction, arrhythmias, and palpitations) was <= 1% and not different between PRANDIN and the comparator drugs. The incidence of total serious cardiovascular adverse events, including ischemia, was higher for repaglinide (4%) than for sulfonylurea drugs (3%) in controlled comparator clinical trials. In 1-year controlled trials, PRANDIN treatment was not associated with excess mortality when compared to the rates observed with other oral hypoglycemic agent therapies"
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Repaglinide&limit=1&skip=14
Page 14 of 18
        "generic_name": [
          "REPAGLINIDE"
        "brand_name": [
          "Repaglinide"
 
      "drug_interactions": [
        "Drug-Drug Interactions In vitro data indicate that repaglinide is metabolized by cytochrome P450 enzymes 2C8 and 3A4. Consequently, repaglinide metabolism may be altered by drugs which influence these cytochrome P450 enzyme systems via induction and inhibition. Caution should therefore be used in patients who are on repaglinide and taking inhibitors and/or inducers of CYP2C8 and CYP3A4. The effect may be very significant if both enzymes are inhibited at the same time resulting in a substantial increase in repaglinide plasma concentrations. Drugs that are known to inhibit CYP3A4 include antifungal agents like ketoconazole, itraconazole, and antibacterial agents like erythromycin. Drugs that are known to inhibit CYP2C8 include agents like trimethoprim, gemfibrozil and montelukast. Drugs that induce the CYP3A4 and/or 2C8 enzyme systems include rifampin, barbiturates, and carbamezapine. See CLINICAL PHARMACOLOGY section, Drug-Drug Interactions . Repaglinide appears to be a substrate for active hepatic uptake transporter (organic anion transporting protein OATP1B1). Drugs that inhibit OATP1B1 (e.g., cyclosporine) may likewise have the potential to increase plasma concentrations of repaglinide. See CLINICAL PHARMACOLOGY section, Drug-Drug Interactions . In vivo data from a study that evaluated the co-administration of a cytochrome P450 enzyme 3A4 inhibitor, clarithromycin, with repaglinide resulted in a clinically significant increase in repaglinide plasma levels. In addition, an increase in repaglinide plasma levels was observed in studies that evaluated the co-administration of repaglinide with trimethoprim and repaglinide with deferasirox, both cytochrome P-450 enzyme 2C8 inhibitors. These increases in repaglinide plasma levels may necessitate a repaglinide dose adjustment. See CLINICAL PHARMACOLOGY section, Drug-Drug Interactions . Gemfibrozil significantly increased repaglinide exposure. Therefore, patients should not take repaglinide with gemfibrozil. See CLINICAL PHARMACOLOGY section, Drug-Drug Interactions , and CONTRAINDICATIONS . The hypoglycemic action of oral blood glucose-lowering agents may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, cyclosporine, chloramphenicol, coumarins, probenecid, monoamine oxidase inhibitors, and beta adrenergic blocking agents. When such drugs are administered to a patient receiving oral blood glucose-lowering agents, the patient should be observed closely for hypoglycemia. When such drugs are withdrawn from a patient receiving oral blood glucose-lowering agents, the patient should be observed closely for loss of glycemic control. Certain drugs tend to produce hyperglycemia and may lead to loss of glycemic control. These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When these drugs are administered to a patient receiving oral blood glucose-lowering agents, the patient should be observed for loss of glycemic control. When these drugs are withdrawn from a patient receiving oral blood glucose-lowering agents, the patient should be observed closely for hypoglycemia."
      "adverse_reactions": [
        "ADVERSE REACTIONS Hypoglycemia: See PRECAUTIONS and OVERDOSAGE sections. Repaglinide has been administered to 2931 individuals during clinical trials. Approximately 1500 of these individuals with type 2 diabetes have been treated for at least 3 months, 1000 for at least 6 months, and 800 for at least 1 year. The majority of these individuals (1228) received repaglinide in one of five 1-year, active-controlled trials. The comparator drugs in these 1-year trials were oral sulfonylurea drugs (SU) including glyburide and glipizide. Over one year, 13% of repaglinide patients were discontinued due to adverse events, as were 14% of SU patients. The most common adverse events leading to withdrawal were hyperglycemia, hypoglycemia, and related symptoms (see PRECAUTIONS ). Mild or moderate hypoglycemia occurred in 16% of repaglinide patients, 20% of glyburide patients, and 19% of glipizide patients. The table below lists common adverse events for repaglinide patients compared to both placebo (in trials 12 to 24 weeks duration) and to glyburide and glipizide in one year trials. The adverse event profile of repaglinide was generally comparable to that for sulfonylurea drugs (SU). Commonly Reported Adverse Events (% of Patients)* EVENT Repaglinide N = 352 PLACEBO N = 108 Repaglinide N = 1228 SU N = 498 Placebo Controlled Studies Active Controlled Studies *: Events >2% for the repaglinide group in the placebo-controlled studies and >= events in the placebo group **: See trial description in CLINICAL PHARMACOLOGY, Clinical Trials Metabolic Hypoglycemia 31** 7 16 20 Respiratory URI 16 8 10 10 Sinusitis 6 2 3 4 Rhinitis 3 3 7 8 Bronchitis 2 1 6 7 Gastrointestinal Nausea 5 5 3 2 Diarrhea 5 2 4 6 Constipation 3 2 2 3 Vomiting 3 3 2 1 Dyspepsia 2 2 4 2 Musculoskeletal Arthralgia 6 3 3 4 Back Pain 5 4 6 7 Other Headache 11 10 9 8 Paresthesia 3 3 2 1 Chest Pain 3 1 2 1 Urinary Tract Infection 2 1 3 3 Tooth disorder 2 0 <1 <1 Allergy 2 0 1 <1 Cardiovascular Events In one-year trials comparing repaglinide to sulfonylurea drugs, the incidence of angina was comparable (1.8%) for both treatments, with an incidence of chest pain of 1.8% for repaglinide and 1% for sulfonylureas. The incidence of other selected cardiovascular events (hypertension, abnormal EKG, myocardial infarction, arrhythmias, and palpitations) was <= 1% and not different between repaglinide and the comparator drugs. The incidence of total serious cardiovascular adverse events, including ischemia, was higher for repaglinide (4%) than for sulfonylurea drugs (3%) in controlled comparator clinical trials. In 1-year controlled trials, repaglinide treatment was not associated with excess mortality when compared to the rates observed with other oral hypoglycemic agent therapies. Summary of Serious Cardiovascular Events (% of total patients with events) in Trials Comparing Repaglinide to Sulfonylureas Total Exposed Repaglinide SU* 1228 498 *: glyburide and glipizide Serious CV Events 4% 3% Cardiac Ischemic Events 2% 2% Deaths due to CV Events 0.5% 0.4% Seven controlled clinical trials included repaglinide combination therapy with NPH-insulin (n=431), insulin formulations alone (n=388) or other combinations (sulfonylurea plus NPH-insulin or repaglinide plus metformin) (n=120). There were six serious adverse events of myocardial ischemia in patients treated with repaglinide plus NPH-insulin from two studies, and one event in patients using insulin formulations alone from another study. Infrequent Adverse Events (<1% of Patients) Less common adverse clinical or laboratory events observed in clinical trials included elevated liver enzymes, thrombocytopenia, leukopenia, and anaphylactoid reactions. Although no causal relationship with repaglinide has been established, postmarketing experience includes reports of the following rare adverse events: alopecia, hemolytic anemia, pancreatitis, Stevens-Johnson syndrome, and severe hepatic dysfunction including jaundice and hepatitis. Combination Therapy with Thiazolidinediones During 24-week treatment clinical trials of repaglinide-rosiglitazone or repaglinide-pioglitazone combination therapy (a total of 250 patients in combination therapy), hypoglycemia (blood glucose < 50 mg/dL) occurred in 7% of combination therapy patients in comparison to 7% for repaglinide monotherapy, and 2% for thiazolidinedione monotherapy. Peripheral edema was reported in 12 out of 250 repaglinide-thiazolidinedione combination therapy patients and 3 out of 124 thiazolidinedione monotherapy patients, with no cases reported in these trials for repaglinide monotherapy. When corrected for dropout rates of the treatment groups, the percentage of patients having events of peripheral edema per 24 weeks of treatment were 5% for repaglinide-thiazolidinedione combination therapy, and 4% for thiazolidinedione monotherapy. There were reports in 2 of 250 patients (0.8%) treated with repaglinide-thiazolidinedione therapy of episodes of edema with congestive heart failure. Both patients had a prior history of coronary artery disease and recovered after treatment with diuretic agents. No comparable cases in the monotherapy treatment groups were reported. Mean change in weight from baseline was +4.9 kg for repaglinide-thiazolidinedione therapy. There were no patients on repaglinide-thiazolidinedione combination therapy who had elevations of liver transaminases (defined as 3 times the upper limit of normal levels)."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Repaglinide&limit=1&skip=15
Page 15 of 18
        "generic_name": [
          "REPAGLINIDE"
        "brand_name": [
          "Repaglinide"
 
      "drug_interactions": [
        "Drug-Drug Interactions In vitro data indicate that repaglinide is metabolized by cytochrome P450 enzymes 2C8 and 3A4. Consequently, repaglinide metabolism may be altered by drugs which influence these cytochrome P450 enzyme systems via induction and inhibition. Caution should therefore be used in patients who are on repaglinide and taking inhibitors and/or inducers of CYP2C8 and CYP3A4. The effect may be very significant if both enzymes are inhibited at the same time resulting in a substantial increase in repaglinide plasma concentrations. Drugs that are known to inhibit CYP3A4 include antifungal agents like ketoconazole, itraconazole, and antibacterial agents like erythromycin. Drugs that are known to inhibit CYP2C8 include agents like trimethoprim, gemfibrozil and montelukast. Drugs that induce the CYP3A4 and/or 2C8 enzyme systems include rifampin, barbiturates, and carbamezapine. (See CLINICAL PHARMACOLOGY: Drug-Drug Interactions.) Repaglinide appears to be a substrate for active hepatic uptake transporter (organic anion transporting protein OATP1B1). Drugs that inhibit OATP1B1 (e.g., cyclosporine) may likewise have the potential to increase plasma concentrations of repaglinide. (See CLINICAL PHARMACOLOGY: Drug-Drug Interactions.) In vivo data from a study that evaluated the coadministration of a cytochrome P450 enzyme 3A4 inhibitor, clarithromycin, with repaglinide resulted in a clinically significant increase in repaglinide plasma levels. In addition, an increase in repaglinide plasma levels was observed in studies that evaluated the coadministration of repaglinide with trimethoprim and repaglinide with deferasirox, both cytochrome P450 enzyme 2C8 inhibitors. These increases in repaglinide plasma levels may necessitate a repaglinide dose adjustment. (See CLINICAL PHARMACOLOGY: Drug-Drug Interactions.) Gemfibrozil significantly increased repaglinide exposure. Therefore, patients should not take repaglinide with gemfibrozil. (See CLINICAL PHARMACOLOGY: Drug-Drug Interactions and CONTRAINDICATIONS.) The hypoglycemic action of oral blood glucose-lowering agents may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, cyclosporine, chloramphenicol, coumarins, probenecid, monoamine oxidase inhibitors, and beta-adrenergic blocking agents. When such drugs are administered to a patient receiving oral blood glucose-lowering agents, the patient should be observed closely for hypoglycemia. When such drugs are withdrawn from a patient receiving oral blood glucose-lowering agents, the patient should be observed closely for loss of glycemic control. Certain drugs tend to produce hyperglycemia and may lead to loss of glycemic control. These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When these drugs are administered to a patient receiving oral blood glucose-lowering agents, the patient should be observed for loss of glycemic control. When these drugs are withdrawn from a patient receiving oral blood glucose-lowering agents, the patient should be observed closely for hypoglycemia."
      "adverse_reactions": [
        "ADVERSE REACTIONS Hypoglycemia See PRECAUTIONS and OVERDOSAGE sections. Repaglinide has been administered to 2,931 individuals during clinical trials. Approximately 1,500 of these individuals with type 2 diabetes have been treated for at least 3 months, 1,000 for at least 6 months, and 800 for at least one year. The majority of these individuals (1,228) received repaglinide in 1 of 5 one-year, active-controlled trials. The comparator drugs in these one-year trials were oral sulfonylurea drugs (SU) including glyburide and glipizide. Over one year, 13% of repaglinide patients were discontinued due to adverse events, as were 14% of SU patients. The most common adverse events leading to withdrawal were hyperglycemia, hypoglycemia, and related symptoms (see PRECAUTIONS). Mild or moderate hypoglycemia occurred in 16% of repaglinide patients, 20% of glyburide patients, and 19% of glipizide patients. The table below lists common adverse events for repaglinide patients compared to both placebo (in trials 12 to 24 weeks duration) and to glyburide and glipizide in one year trials. The adverse event profile of repaglinide was generally comparable to that for sulfonylurea drugs (SU). Commonly Reported Adverse Events (% of Patients)Events >= 2% for the repaglinide group in the placebo-controlled studies and >= events in the placebo group EVENT REPAGLINIDE N = 352 PLACEBO N = 108 REPAGLINIDE N = 1,228 SU N = 498 Placebo controlled studies Active controlled studies Metabolic Hypoglycemia 31See trial description in CLINICAL PHARMACOLOGY: Clinical Trials 7 16 20 Respiratory URI Sinusitis Rhinitis Bronchitis 16 6 3 2 8 2 3 1 10 3 7 6 10 4 8 7 Gastrointestinal Nausea Diarrhea Constipation Vomiting Dyspepsia 5 5 3 3 2 5 2 2 3 2 3 4 2 2 4 2 6 3 1 2 Musculoskeletal Arthralgia Back pain 6 5 3 4 3 6 4 7 Other Headache Paresthesia Chest pain Urinary tract infection Tooth disorder Allergy 11 3 3 2 2 2 10 3 1 1 0 0 9 2 2 3 < 1 1 8 1 1 3 < 1 < 1 Cardiovascular Events In one-year trials comparing repaglinide to sulfonylurea drugs, the incidence of angina was comparable (1.8%) for both treatments, with an incidence of chest pain of 1.8% for repaglinide and 1% for sulfonylureas. The incidence of other selected cardiovascular events (hypertension, abnormal EKG, myocardial infarction, arrhythmias, and palpitations) was <= 1% and not different between repaglinide and the comparator drugs. The incidence of total serious cardiovascular adverse events, including ischemia, was higher for repaglinide (4%) than for sulfonylurea drugs (3%) in controlled comparator clinical trials. In one-year controlled trials, repaglinide treatment was not associated with excess mortality when compared to the rates observed with other oral hypoglycemic agent therapies. Summary of Serious Cardiovascular Events (% of Total Patients with Events) in Trials Comparing Repaglinide to Sulfonylureas Repaglinide SUglyburide and glipizide Total Exposed 1,228 498 Serious CV Events 4% 3% Cardiac Ischemic Events 2% 2% Deaths due to CV Events 0.5% 0.4% Seven controlled clinical trials included repaglinide combination therapy with NPH-insulin (n = 431), insulin formulations alone (n = 388) or other combinations (sulfonylurea plus NPH-insulin or repaglinide plus metformin) (n = 120). There were six serious adverse events of myocardial ischemia in patients treated with repaglinide plus NPH-insulin from two studies, and one event in patients using insulin formulations alone from another study. Infrequent Adverse Events (< 1% of Patients) Less common adverse clinical or laboratory events observed in clinical trials included elevated liver enzymes, thrombocytopenia, leukopenia, and anaphylactoid reactions. Although no causal relationship with repaglinide has been established, post-marketing experience includes reports of the following rare adverse events: alopecia, hemolytic anemia, pancreatitis, Stevens-Johnson Syndrome, and severe hepatic dysfunction including jaundice and hepatitis. Combination Therapy with Thiazolidinediones During 24-week treatment clinical trials of repaglinide-rosiglitazone or repaglinide-pioglitazone combination therapy (a total of 250 patients in combination therapy), hypoglycemia (blood glucose < 50 mg/dL) occurred in 7% of combination therapy patients in comparison to 7% for repaglinide monotherapy, and 2% for thiazolidinedione monotherapy. Peripheral edema was reported in 12 out of 250 repaglinide-thiazolidinedione combination therapy patients and 3 out of 124 thiazolidinedione monotherapy patients, with no cases reported in these trials for repaglinide monotherapy. When corrected for dropout rates of the treatment groups, the percentage of patients having events of peripheral edema per 24 weeks of treatment were 5% for repaglinide-thiazolidinedione combination therapy, and 4% for thiazolidinedione monotherapy. There were reports in 2 of 250 patients (0.8%) treated with repaglinide-thiazolidinedione therapy of episodes of edema with congestive heart failure. Both patients had a prior history of coronary artery disease and recovered after treatment with diuretic agents. No comparable cases in the monotherapy treatment groups were reported. Mean change in weight from baseline was +4.9 kg for repaglinide-thiazolidinedione therapy. There were no patients on repaglinide-thiazolidinedione combination therapy who had elevations of liver transaminases (defined as 3 times the upper limit of normal levels)."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Repaglinide&limit=1&skip=16
Page 16 of 18
        "generic_name": [
          "REPAGLINIDE"
        "brand_name": [
          "Prandin"
 
      "drug_interactions": [
        "Drug-Drug Interactions data indicate that PRANDIN is metabolized by cytochrome P450 enzymes 2C8 and 3A4. Consequently, repaglinide metabolism may be altered by drugs which influence these cytochrome P450 enzyme systems via induction and inhibition. Caution should therefore be used in patients who are on PRANDIN and taking inhibitors and/or inducers of CYP2C8 and CYP3A4. The effect may be very significant if both enzymes are inhibited at the same time resulting in a substantial increase in repaglinide plasma concentrations. Drugs that are known to inhibit CYP3A4 include antifungal agents like ketoconazole, itraconazole, and antibacterial agents like erythromycin. Drugs that are known to inhibit CYP2C8 include agents like trimethoprim, gemfibrozil and montelukast. Drugs that induce the CYP3A4 and/or 2C8 enzyme systems include rifampin, barbiturates, and carbamezapine. See section, . In vitro CLINICAL PHARMACOLOGY Drug-Drug Interactions Repaglinide appears to be a substrate for active hepatic uptake transporter (organic anion transporting protein OATP1B1). Drugs that inhibit OATP1B1 (e.g. cyclosporine) may likewise have the potential to increase plasma concentrations of repaglinide. See section, . CLINICAL PHARMACOLOGY Drug-Drug Interactions data from a study that evaluated the co-administration of a cytochrome P450 enzyme 3A4 inhibitor, clarithromycin, with PRANDIN resulted in a clinically significant increase in repaglinide plasma levels. In addition, an increase in repaglinide plasma levels was observed in studies that evaluated the co-administration of PRANDIN with trimethoprim and PRANDIN with deferasirox, both cytochrome P-450 enzyme 2C8 inhibitors. These increases in repaglinide plasma levels may necessitate a PRANDIN dose adjustment. See section, . In vivo CLINICAL PHARMACOLOGY Drug-Drug Interactions Gemfibrozil significantly increased PRANDIN exposure. Therefore, patients should not take PRANDIN with gemfibrozil. See section, , and . CLINICAL PHARMACOLOGY Drug-Drug Interactions CONTRAINDICATIONS The hypoglycemic action of oral blood glucose-lowering agents may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, cyclosporine, chloramphenicol, coumarins, probenecid, monoamine oxidase inhibitors, and beta adrenergic blocking agents. When such drugs are administered to a patient receiving oral blood glucose-lowering agents, the patient should be observed closely for hypoglycemia. When such drugs are withdrawn from a patient receiving oral blood glucose-lowering agents, the patient should be observed closely for loss of glycemic control. Certain drugs tend to produce hyperglycemia and may lead to loss of glycemic control. These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When these drugs are administered to a patient receiving oral blood glucose-lowering agents, the patient should be observed for loss of glycemic control. When these drugs are withdrawn from a patient receiving oral blood glucose-lowering agents, the patient should be observed closely for hypoglycemia."
      "adverse_reactions": [
        "ADVERSE REACTIONS Hypoglycemia: See and sections. PRECAUTIONS OVERDOSAGE PRANDIN has been administered to 2931 individuals during clinical trials. Approximately 1500 of these individuals with type 2 diabetes have been treated for at least 3 months, 1000 for at least 6 months, and 800 for at least 1 year. The majority of these individuals (1228) received PRANDIN in one of five 1-year, active-controlled trials. The comparator drugs in these 1-year trials were oral sulfonylurea drugs (SU) including glyburide and glipizide. Over one year, 13% of PRANDIN patients were discontinued due to adverse events, as were 14% of SU patients. The most common adverse events leading to withdrawal were hyperglycemia, hypoglycemia, and related symptoms (see ). Mild or moderate hypoglycemia occurred in 16% of PRANDIN patients, 20% of glyburide patients, and 19% of glipizide patients. PRECAUTIONS The table below lists common adverse events for PRANDIN patients compared to both placebo (in trials 12 to 24 weeks duration) and to glyburide and glipizide in one year trials. The adverse event profile of PRANDIN was generally comparable to that for sulfonylurea drugs (SU). Commonly Reported Adverse Events (% of Patients) Events >= 2% for the PRANDIN group in the placebo-controlled studies and >= events in the placebo group EVENT PRANDIN PLACEBO PRANDIN SU N = 352 N = 108 N = 1228 N = 498 Placebo controlled studies Active controlled studies Metabolic Hypoglycemia 31 See trial description in , CLINICAL PHARMACOLOGY Clinical Trials 7 16 20 Respiratory URI 16 8 10 10 Sinusitis 6 2 3 4 Rhinitis 3 3 7 8 Bronchitis 2 1 6 7 Gastrointestinal Nausea 5 5 3 2 Diarrhea 5 2 4 6 Constipation 3 2 2 3 Vomiting 3 3 2 1 Dyspepsia 2 2 4 2 Musculoskeletal Arthralgia 6 3 3 4 Back Pain 5 4 6 7 Other Headache 11 10 9 8 Paresthesia 3 3 2 1 Chest pain 3 1 2 1 Urinary tract infection 2 1 3 3 Tooth disorder 2 0 <1 <1 Allergy 2 0 1 <1 Cardiovascular Events In one-year trials comparing PRANDIN to sulfonylurea drugs, the incidence of angina was comparable (1.8%) for both treatments, with an incidence of chest pain of 1.8% for PRANDIN and 1.0% for sulfonylureas. The incidence of other selected cardiovascular events (hypertension, abnormal EKG, myocardial infarction, arrhythmias, and palpitations) was <= 1% and not different between PRANDIN and the comparator drugs. The incidence of total serious cardiovascular adverse events, including ischemia, was higher for repaglinide (4%) than for sulfonylurea drugs (3%) in controlled comparator clinical trials. In 1-year controlled trials, PRANDIN treatment was not associated with excess mortality when compared to the rates observed with other oral hypoglycemic agent therapies. Summary of Serious Cardiovascular Events (% of total patients with events) in Trials Comparing PRANDIN to Sulfonylureas PRANDIN SU glyburide and glipizide Total Exposed 1228 498 Serious CV Events 4% 3% Cardiac Ischemic Events 2% 2% Deaths due to CV Events 0.5% 0.4% Seven controlled clinical trials included PRANDIN combination therapy with NPH-insulin (n=431), insulin formulations alone (n=388) or other combinations (sulfonylurea plus NPH-insulin or PRANDIN plus metformin) (n=120). There were six serious adverse events of myocardial ischemia in patients treated with PRANDIN plus NPH-insulin from two studies, and one event in patients using insulin formulations alone from another study. Infrequent Adverse Events (<1% of Patients) Less common adverse clinical or laboratory events observed in clinical trials included elevated liver enzymes, thrombocytopenia, leukopenia, and anaphylactoid reactions. Although no causal relationship with repaglinide has been established, postmarketing experience includes reports of the following rare adverse events: alopecia, hemolytic anemia, pancreatitis, Stevens-Johnson Syndrome, and severe hepatic dysfunction including jaundice and hepatitis. Combination Therapy with Thiazolidinediones During 24-week treatment clinical trials of PRANDIN-rosiglitazone or PRANDIN-pioglitazone combination therapy (a total of 250 patients in combination therapy), hypoglycemia (blood glucose < 50 mg/dL) occurred in 7% of combination therapy patients in comparison to 7% for PRANDIN monotherapy, and 2% for thiazolidinedione monotherapy. Peripheral edema was reported in 12 out of 250 PRANDIN-thiazolidinedione combination therapy patients and 3 out of 124 thiazolidinedione monotherapy patients, with no cases reported in these trials for PRANDIN monotherapy. When corrected for dropout rates of the treatment groups, the percentage of patients having events of peripheral edema per 24 weeks of treatment were 5% for PRANDIN-thiazolidinedione combination therapy, and 4% for thiazolidinedione monotherapy. There were reports in 2 of 250 patients (0.8%) treated with PRANDIN-thiazolidinedione therapy of episodes of edema with congestive heart failure. Both patients had a prior history of coronary artery disease and recovered after treatment with diuretic agents. No comparable cases in the monotherapy treatment groups were reported. Mean change in weight from baseline was +4.9 kg for PRANDIN-thiazolidinedione therapy. There were no patients on PRANDIN-thiazolidinedione combination therapy who had elevations of liver transaminases (defined as 3 times the upper limit of normal levels)."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Repaglinide&limit=1&skip=17
Page 17 of 18
        "generic_name": [
          "REPAGLINIDE"
        "brand_name": [
          "REPAGLINIDE"
 
      "drug_interactions": [
        "Drug-Drug Interactions In vitro data indicate that repaglinide is metabolized by cytochrome P450 enzymes 2C8 and 3A4. Consequently, repaglinide metabolism may be altered by drugs which influence these cytochrome P450 enzyme systems via induction and inhibition. Caution should therefore be used in patients who are on Repaglinide Tablets and taking inhibitors and/or inducers of CYP2C8 and CYP3A4. The effect may be very significant if both enzymes are inhibited at the same time resulting in a substantial increase in repaglinide plasma concentrations. Drugs that are known to inhibit CYP3A4 include antifungal agents like ketoconazole, itraconazole, and antibacterial agents like erythromycin. Drugs that are known to inhibit CYP2C8 include agents like trimethoprim, gemfibrozil and montelukast. Drugs that induce the CYP3A4 and/or 2C8 enzyme systems include rifampin, barbiturates, and carbamezapine. See CLINICAL PHARMACOLOGY section, Drug-Drug Interactions . Repaglinide appears to be a substrate for active hepatic uptake transporter (organic anion transporting protein OATP1B1). Drugs that inhibit OATP1B1 (e.g. cyclosporine) may likewise have the potential to increase plasma concentrations of repaglinide. See CLINICAL PHARMACOLOGY section, Drug-Drug Interactions . In vivo data from a study that evaluated the co-administration of a cytochrome P450 enzyme 3A4 inhibitor, clarithromycin, with Repaglinide Tablets resulted in a clinically significant increase in repaglinide plasma levels. In addition, an increase in repaglinide plasma levels was observed in studies that evaluated the co-administration of Repaglinide Tablets with trimethoprim and Repaglinide Tablets with deferasirox, both cytochrome P-450 enzyme 2C8 inhibitors. These increases in repaglinide plasma levels may necessitate a Repaglinide Tablets dose adjustment. See CLINICAL PHARMACOLOGY section, Drug-Drug Interactions . Gemfibrozil significantly increased repaglinide exposure. Therefore, patients should not take Repaglinide Tablets with gemfibrozil. See CLINICAL PHARMACOLOGY section, Drug-Drug Interactions , and CONTRAINDICATIONS. The hypoglycemic action of oral blood glucose-lowering agents may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, cyclosporine, chloramphenicol, coumarins, probenecid, monoamine oxidase inhibitors, and beta adrenergic blocking agents. When such drugs are administered to a patient receiving oral blood glucose-lowering agents, the patient should be observed closely for hypoglycemia. When such drugs are withdrawn from a patient receiving oral blood glucose-lowering agents, the patient should be observed closely for loss of glycemic control. Certain drugs tend to produce hyperglycemia and may lead to loss of glycemic control. These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When these drugs are administered to a patient receiving oral blood glucose-lowering agents, the patient should be observed for loss of glycemic control. When these drugs are withdrawn from a patient receiving oral blood glucose-lowering agents, the patient should be observed closely for hypoglycemia."
      "adverse_reactions": [
        "ADVERSE REACTIONS Hypoglycemia: See PRECAUTIONS and OVERDOSAGE sections. Repaglinide Tablets have been administered to 2931 individuals during clinical trials. Approximately 1500 of these individuals with type 2 diabetes have been treated for at least 3 months, 1000 for at least 6 months, and 800 for at least 1 year. The majority of these individuals (1228) received Repaglinide Tablets in one of five 1-year, active-controlled trials. The comparator drugs in these 1-year trials were oral sulfonylurea drugs (SU) including glyburide and glipizide. Over one year, 13% of Repaglinide Tablets patients were discontinued due to adverse events, as were 14% of SU patients. The most common adverse events leading to withdrawal were hyperglycemia, hypoglycemia, and related symptoms (see PRECAUTIONS ). Mild or moderate hypoglycemia occurred in 16% of Repaglinide Tablets patients, 20% of glyburide patients, and 19% of glipizide patients. The table below lists common adverse events for Repaglinide Tablets patients compared to both placebo (in trials 12 to 24 weeks duration) and to glyburide and glipizide in one year trials. The adverse event profile of Repaglinide Tablets was generally comparable to that for sulfonylurea drugs (SU). To report SUSPECTED ADVERSE REACTIONS, contact Breckenridge Pharmaceutical, Inc. at 1-800-367-3395 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Commonly Reported Adverse Events (% of Patients): Events >=2% for the Repaglinide Tablets group in the placebo-controlled studies and >= events in the placebo group EVENT Repaglinide Tablets PLACEBO Repaglinide Tablets SU N = 352 N = 108 N = 1228 N = 498 Placebo controlled studies Active controlled studies Metabolic Hypoglycemia 31: See trial description in CLINICAL PHARMACOLOGY, Clinical Trials 7 16 20 Respiratory URI 16 8 10 10 Sinusitis 6 2 3 4 Rhinitis 3 3 7 8 Bronchitis 2 1 6 7 Gastrointestinal Nausea 5 5 3 2 Diarrhea 5 2 4 6 Constipation 3 2 2 3 Vomiting 3 3 2 1 Dyspepsia 2 2 4 2 Musculoskeletal Arthralgia 6 3 3 4 Back Pain 5 4 6 7 Other Headache 11 10 9 8 Paresthesia 3 3 2 1 Chest pain 3 1 2 1 Urinary tract infection 2 1 3 3 Tooth disorder 2 0 <1 <1 Allergy 2 0 1 <1 Cardiovascular Events In one-year trials comparing Repaglinide Tablets to sulfonylurea drugs, the incidence of angina was comparable (1.8%) for both treatments, with an incidence of chest pain of 1.8% for Repaglinide Tablets and 1.0% for sulfonylureas. The incidence of other selected cardiovascular events (hypertension, abnormal EKG, myocardial infarction, arrhythmias, and palpitations) was <= 1% and not different between Repaglinide Tablets and the comparator drugs. The incidence of total serious cardiovascular adverse events, including ischemia, was higher for repaglinide (4%) than for sulfonylurea drugs (3%) in controlled comparator clinical trials. In 1-year controlled trials, Repaglinide Tablets treatment was not associated with excess mortality when compared to the rates observed with other oral hypoglycemic agent therapies. Summary of Serious Cardiovascular Events (% of total patients with events) in Trials Comparing Repaglinide Tablets to Sulfonylureas Repaglinide Tablets SU: glyburide and glipizide Total Exposed 1228 498 Serious CV Events 4% 3% Cardiac Ischemic Events 2% 2% Deaths due to CV Events 0.5% 0.4% Seven controlled clinical trials included Repaglinide Tablets combination therapy with NPH-insulin (n=431), insulin formulations alone (n=388) or other combinations (sulfonylurea plus NPH-insulin or Repaglinide Tablets plus metformin) (n=120). There were six serious adverse events of myocardial ischemia in patients treated with Repaglinide Tablets plus NPH-insulin from two studies, and one event in patients using insulin formulations alone from another study. Infrequent Adverse Events (<1% of Patients) Less common adverse clinical or laboratory events observed in clinical trials included elevated liver enzymes, thrombocytopenia, leukopenia, and anaphylactoid reactions. Although no causal relationship with repaglinide has been established, postmarketing experience includes reports of the following rare adverse events: alopecia, hemolytic anemia, pancreatitis, Stevens-Johnson Syndrome, and severe hepatic dysfunction including jaundice and hepatitis. Combination Therapy with Thiazolidinediones During 24-week treatment clinical trials of Repaglinide Tablets-rosiglitazone or Repaglinide Tablets-pioglitazone combination therapy (a total of 250 patients in combination therapy), hypoglycemia (blood glucose < 50 mg/dL) occurred in 7% of combination therapy patients in comparison to 7% for Repaglinide Tablets monotherapy, and 2% for thiazolidinedione monotherapy. Peripheral edema was reported in 12 out of 250 Repaglinide Tablets-thiazolidinedione combination therapy patients and 3 out of 124 thiazolidinedione monotherapy patients, with no cases reported in these trials for Repaglinide Tablets monotherapy. When corrected for dropout rates of the treatment groups, the percentage of patients having events of peripheral edema per 24 weeks of treatment were 5% for Repaglinide Tablets-thiazolidinedione combination therapy, and 4% for thiazolidinedione monotherapy. There were reports in 2 of 250 patients (0.8%) treated with Repaglinide Tablets-thiazolidinedione therapy of episodes of edema with congestive heart failure. Both patients had a prior history of coronary artery disease and recovered after treatment with diuretic agents. No comparable cases in the monotherapy treatment groups were reported. Mean change in weight from baseline was +4.9 kg for Repaglinide Tablets-thiazolidinedione therapy. There were no patients on Repaglinide Tablets-thiozolidinedione combination therapy who had elevations of liver transaminases (defined as 3 times the upper limit of normal levels)."
 
 
--------------------------------------------------------------------------------------------------------------------
